If you invest in our common stock, your interest will be diluted to the
extent of the difference between the public offering price per share and the
pro forma as adjusted net tangible book value per share after this offering.
Investors participating in this offering will incur immediate, substantial
dilution. The pro forma net tangible book value of our common stock as of June
30, 2001 was approximately $13.0 million, or approximately $0.70 per share. Pro
forma net tangible book value per share represents the amount of our total
tangible assets less total liabilities, divided by the number of shares of
common stock outstanding after giving effect to the conversion of all
outstanding shares of our preferred stock into common stock. After giving
effect to our sale of shares of common stock in this offering at an
assumed initial public offering price of $ per share and after deducting the
estimated underwriting discount and estimated offering expenses payable by us,
and after application of a portion of the estimated proceeds to repay
indebtedness as described under "Use of Proceeds," our pro forma as adjusted
net tangible book value at June 30, 2001 would have been $ , or $ per
share. This represents an immediate increase in pro forma net tangible book
value of $ per share to existing stockholders and an immediate dilution of
$ per share to purchasers of common stock in this offering. The following
table illustrates this dilution:
Assumed initial public offering price per share................. $
Pro forma net tangible book value per share at June 30,
2001......................................................... $0.70
Increase per share attributable to new investors..............
-----
Pro forma as adjusted net tangible book value per share after
this offering..................................................
---
Dilution per share to new investors............................. $
---
The following table sets forth on a pro forma as adjusted basis, as of June
30, 2001, the total number of shares of common stock purchased from us, the
total consideration paid for these shares and the average price per share paid
by existing stockholders and new investors, before deducting the estimated
underwriting discount and estimated offering expenses payable by us.
Shares Purchased Total Consideration
------------------ ------------------- Average Price
Number Percent Amount Percent Per Share
---------- ------- ----------- ------- -------------
Existing stockholders ..... 18,591,832 $39,160,000 $2.11
New investors..............
---------- ------ ----------- ------ -----
Total ................... 100.0% 100.0%
========== ====== =========== ====== =====
As of June 30, 2001, we had 2,425,016 shares of common stock issuable upon
exercise of options outstanding at a weighted-average exercise price of $1.66
per share and 39,000 shares of common stock issuable upon exercise of
outstanding warrants with an exercise price of $1.70 per share. We have
reserved 1,455,003 shares of common stock for future issuance under our stock
option plans and 350,000 shares of common stock under our 2001 employee stock
purchase plan. To the extent these options or warrants are exercised, and to
the extent we issue new options or rights under our stock option plans or issue
additional shares of common stock in the future, purchasers of common stock in
this offering will experience further dilution.
21
SELECTED CONSOLIDATED FINANCIAL DATA
The selected consolidated financial data set forth below should be read in
conjunction with our consolidated financial statements and the related notes
and "Management's Discussion and Analysis of Financial Condition and Results of
Operations" included elsewhere in this prospectus. We derived the consolidated
statement of operations data for the years ended December 31, 1998, 1999 and
2000 and the consolidated balance sheet data as of December 31, 1999 and 2000
from the consolidated financial statements which have been audited by Ernst &
Young LLP and included elsewhere in this prospectus. The consolidated statement
of operations data for the six months ended June 30, 2000 and 2001 and the
consolidated balance sheet data as of June 30, 2001 have been derived from our
unaudited financial statements included elsewhere in this prospectus. We
derived the consolidated statement of operations data for the years ended
December 31, 1996 and 1997 and the consolidated balance sheet data as of
December 31, 1996, 1997 and 1998 from audited consolidated financial statements
which are not included elsewhere in this prospectus. In the opinion of
management, the unaudited consolidated financial statements have been prepared
on the same basis as the audited consolidated financial statements and contain
all adjustments, consisting only of normal recurring adjustments, necessary for
a fair presentation of our results of operations for these periods and
financial condition at those dates. Historical results are not necessarily
indicative of future results.
See note 2 to the consolidated financial statements for an explanation of
the method used to determine the numbers of shares used in computing basic and
diluted and pro forma basic and diluted net loss per share.
Six Months
Years Ended December 31, Ended June 30,
------------------------------------------- ----------------
1996 1997 1998 1999 2000 2000 2001
------ ------- ------- ------- -------- ------- -------
(In thousands, except per share data)
Consolidated statement of operations
data:
Revenues:
Product sales......................... $ -- $ -- $ -- $ -- $ 502 $ -- $ 428
Research revenue...................... 30 55 110 77 218 75 117
------ ------- ------- ------- -------- ------- -------
Total revenues...................... 30 55 110 77 720 75 545
Operating costs and expenses:
Cost of product sales................. -- -- -- -- 502 -- 484
Manufacturing plant start-up costs.... -- -- -- -- -- -- 295
Research and development.............. 387 1,780 3,090 4,468 6,300 3,558 2,651
Selling, general and administrative... 138 403 836 1,749 2,914 1,191 1,777
Stock option compensation............. -- 10 15 12 224 14 301
------ ------- ------- ------- -------- ------- -------
Total operating costs and expenses.. 525 2,193 3,941 6,229 9,940 4,763 5,508
------ ------- ------- ------- -------- ------- -------
Loss from operations.................... (495) (2,138) (3,831) (6,152) (9,220) (4,688) (4,963)
Interest income, net.................... 4 86 170 68 134 51 191
------ ------- ------- ------- -------- ------- -------
Net loss................................ (491) (2,052) (3,661) (6,084) (9,086) (4,637) (4,772)
Preferred stock accretion............... -- -- (341) (810) (1,496) (642) (1,395)
------ ------- ------- ------- -------- ------- -------
Net loss applicable to common
stockholders........................... $ (491) $(2,052) $(4,002) $(6,894) $(10,582) $(5,279) $(6,167)
====== ======= ======= ======= ======== ======= =======
Basic and diluted net loss per share
applicable to common stockholders...... $(0.17) $ (0.67) $ (1.30) $ (2.20) $ (3.07) $ (1.55) $ (1.70)
====== ======= ======= ======= ======== ======= =======
Shares used in computing basic and
diluted net loss applicable to common
stockholders........................... 2,955 3,068 3,068 3,140 3,451 3,399 3,620
====== ======= ======= ======= ======== ======= =======
Pro forma basic and diluted net loss per
share applicable to common
stockholders........................... $ (0.61) $ (0.26)
======== =======
Shares used in computing pro forma basic
and diluted net loss per share
applicable to common stockholders...... 14,802 18,524
======== =======
22
As of December 31,
-------------------------------------------- As of June 30,
1996 1997 1998 1999 2000 2001
------ ------- ------- -------- -------- --------------
(In thousands)
Consolidated balance
sheet data:
Cash and cash
equivalents............ $1,680 $ 776 $ 2,956 $ 2,849 $ 12,518 $ 6,359
Working capital......... 1,515 656 2,574 2,214 13,422 7,949
Total assets............ 1,712 1,016 3,934 5,436 24,445 19,355
Notes payable and
capital lease
obligations, net of
current portion........ 7 79 433 369 5,340 5,206
Convertible preferred
stock.................. 1,877 3,149 9,396 17,252 40,858 42,239
Accumulated deficit..... (761) (2,813) (6,815) (13,709) (24,291) (30,458)
Total stockholders'
equity (deficit)....... (337) (2,379) (6,366) (13,142) (23,409) (29,218)
23
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Since our inception in January 1995, we have focused on discovering,
developing, manufacturing and marketing effective, safe and environmentally
friendly pest management products for the agricultural and institutional and
home markets. We have devoted substantially all of our efforts toward research
and development activities and have recently commenced marketing and sales
efforts for Serenade, our first natural pest management product.
We incurred net losses of $3.7 million in 1998, $6.1 million in 1999, $9.1
million in 2000 and $4.8 million for the six months ended June 30, 2001. As of
June 30, 2001, we had an accumulated deficit of $30.5 million. We expect to
incur additional losses and to expend substantial financial resources to
continue our research and development activities, enhance our manufacturing
capabilities, expand our sales and marketing activities and for other general
corporate purposes. We anticipate our research and development expenses will
increase as we continue to develop new products and conduct field trials. Our
selling and marketing expenses will increase as we commercialize Serenade, and
general and administrative expenses will increase as we enhance our facilities
and increase personnel.
We began commercial production of Serenade in the third quarter of 2000. We
recognize revenues from product sales upon shipment to distributors, unless
contractual obligations, acceptance provisions or other contingencies exist. If
these obligations or provisions exist, we recognize revenues after they are
fulfilled or expire. Distributors do not have price protection or return
rights. We generate research revenues from research and development activities
under contracts with other entities. We recognize revenues from "best efforts"
research and development contracts as work is performed. If, however, the
contracts provide for specific milestones or deliverables, we recognize
revenues upon the achievement of those milestones or upon delivery. We record
funding received in advance of work performed, including up-front payments, as
deferred revenue. We may receive payments under strategic collaboration
agreements as collaborators or their sublicensees achieve product development
milestones as well as royalty payments based on sales of products that
incorporate our proprietary technology. We will recognize any future milestone
payments or royalty revenues as earned.
We have deferred the recognition of revenue for some sales transactions that
provide for payment terms of relatively longer duration. During the six months
ended June 30, 2001, we deferred recognition of $334,000 of this type of
revenue. For transactions with these longer payment terms, our policy is to
recognize revenue upon the earlier of cash received or the original invoice due
date, assuming it is probable that we will collect at that date. As of June 30,
2001, transactions with these longer payment terms have original invoice due
dates in August 2001.
Until we purchased our manufacturing facility in Tlaxcala, Mexico in
December 2000, we relied on third-party manufacturers to produce our products.
We believe our production costs through our own manufacturing facility will be
lower than the costs of using third-party manufacturers.
We have recorded deferred stock option compensation in connection with the
grant of stock options to employees based on the difference between the
exercise price of the options and the fair value of our common stock on the
grant date. We determined fair value based on the business factors underlying
the value of our common stock on the grant date.
We recorded deferred stock option compensation expense of $528,000 for the
year ended December 31, 2000 and $710,000 for the six months ended June 30,
2001. These amounts were recorded as a component of stockholders' equity and
are being amortized as charges to operations over the vesting periods of the
options, generally five years, using a graded-vesting method. We recorded stock
option compensation expense of approximately $74,000 for the year ended
December 31, 2000 and $212,000 for the six months ended June 30,
24
2001. For options granted to employees, we expect to record stock option
compensation expense as follows: approximately $282,000 for the remainder of
2001, $350,000 in 2002, $185,000 in 2003, $98,000 in 2004, $35,000 in 2005, and
$2,000 in 2006. The amount of stock option compensation expense to be recorded
in future periods may decrease if unvested options for which deferred stock
option compensation has been recorded are subsequently canceled.
We have also recorded stock option compensation for options granted to
consultants in accordance with Emerging Issues Task Force No. 96-18,
"Accounting for Equity Instruments That Are Issued to Other Than Employees for
Acquiring, or in Conjunction with Selling, Goods or Services." For the years
ended December 31, 1998, 1999 and 2000 and for the six months ended June 30,
2000 and 2001, we recorded stock compensation expense of $15,000, $12,000,
$150,000, $14,000 and $89,000, respectively, relating to options granted to
consultants. Stock option compensation expense incurred as a result of stock
option grants to consultants is an estimate based on the fair market value of
our common stock.
Results of Operations
Six Months Ended June 30, 2000 and 2001
Revenues
Product sales were recorded for the first time in the third quarter of 2000.
For the six months ended June 30, 2001, we recorded $428,000 in revenues for
shipments of Serenade. Three distributors accounted for 83% of product sales
during this period. We expect that a relatively small number of distributors
will continue to account for a significant percentage of product sales.
Research revenues were $75,000 and $117,000 for the six months ended June 30,
2000 and 2001, respectively, and resulted primarily from research revenues
under "best efforts" research and development agreements.
Cost of product sales
Cost of product sales was $484,000 for the six months ended June 30, 2001
and represents expenses incurred in connection with the manufacture of pre-
production batches of Serenade, which yielded saleable quantities of Serenade.
Manufacturing plant start-up costs
Manufacturing plant start-up costs were $295,000 for the six months ended
June 30, 2001 and represent expenses incurred through June 30, 2001 in
connection with one-time activities related to opening our new manufacturing
facility in Tlaxcala, Mexico. This facility was purchased in December 2000.
Costs associated with start-up activities were primarily related to the
operating costs incurred during the pre-production period, including a portion
of salary-related expenses for employees in Mexico, travel costs for the
implementation team, consulting fees and routine maintenance costs. These costs
exclude expenditures relating to constructing and developing long-lived assets
and getting these assets ready for their expected use.
Research and development
Research and development expenses include costs associated with the design,
development and testing of Serenade and our product candidates. These costs
consist primarily of salaries and other personnel-related expenses, as well as
field trial laboratory, pilot plant and equipment expenses. Research and
development expenses were $3.6 million and $2.7 million for the six months
ended June 30, 2000 and 2001, respectively, representing a decrease of $0.9
million. This decrease was primarily due to process development costs for
Serenade incurred in 2000 which were not present in 2001. In the absence of
these process development costs, research and development expenses would have
increased due to higher staffing levels and increases in the number of field
trials conducted.
25
Selling, general and administrative
Selling, general and administrative expenses include salaries and personnel-
related expenses, marketing and recruiting costs, professional service fees and
general corporate expenses. Selling, general and administrative expenses were
$1.2 million and $1.8 million for the six months ended June 30, 2000 and 2001,
respectively, representing an increase of $0.6 million. This increase was
primarily attributable to increases in marketing expenses and employee
compensation costs.
Stock option compensation
Stock option compensation expenses were $14,000 and $301,000 for the six
months ended June 30, 2000 and 2001, respectively. This increase was primarily
attributable to the amortization of deferred stock option compensation.
Interest income, net
Net interest income increased from $51,000 for the six months ended June 30,
2000 to $191,000 for the six months ended June 30, 2001. This increase resulted
from increased interest income earned on higher average cash balances as a
result of funds received from the sale of our preferred stock in December 2000.
Preferred stock accretion
The adjustment to accrete the carrying amount of our convertible preferred
stock to its redemption amount increased from $642,000 for the six months ended
June 30, 2000 to $1.4 million for the six months ended June 30, 2001. This
increase is related to the sale of our convertible preferred stock in December
2000.
Net loss applicable to common stockholders
Net loss applicable to common stockholders increased slightly from $5.3
million for the six months ended June 30, 2000 to $6.2 million for the six
months ended June 30, 2001. The increase was attributable to marketing
expenses, employee compensation costs, including stock option compensation, and
accretion of our convertible preferred stock to its redemption amount,
partially offset by the decrease in process development costs for Serenade.
Years ended December 31, 1998, 1999 and 2000
Revenues
Product sales were $502,000 in 2000. Four distributors accounted for 89% of
product sales during this period. We did not generate revenues from product
sales prior to 2000. Research revenues were $110,000, $77,000 and $218,000 in
1998, 1999 and 2000, respectively, and resulted primarily from research and
development activities under "best efforts" contracts for other entities. The
fluctuation in research revenues was primarily due to timing of the work
performed.
Cost of Product Sales
Cost of product sales was $502,000 in 2000 and represents expenses incurred
in connection with the manufacture of pre-production batches of Serenade, which
yielded saleable quantities of Serenade. These expenses were initially
capitalized at the lower of cost or market and included in inventories.
Research and development
Research and development expenses increased from $3.1 million in 1998 to
$4.5 million in 1999 to $6.3 million in 2000. These increases were primarily
due to increases in the number of personnel as we expanded our product
development efforts, costs associated with the development and regulatory
approval of Serenade and increases in the number of field trials conducted.
26
Selling, general and administrative
Selling, general and administrative expenses increased from $836,000 in 1998
to $1.7 million in 1999 to $2.9 million in 2000. These increases were primarily
attributable to increases in the number of personnel and salaries, marketing
expenses incurred relating to the introduction of Serenade and increases in
professional service fees as a result of growth in our business activities.
Stock option compensation
Stock compensation expenses were $15,000 in 1998, $12,000 in 1999 and
$224,000 in 2000. Expenses incurred primarily represent an estimate of the fair
value of options granted to consultants during these periods.
Interest income, net
Net interest income decreased from $170,000 in 1998 to $68,000 in 1999 and
increased to $134,000 in 2000. The decrease in 1999 resulted from lower average
cash balances as a result of an increase in cash used in operations. The
increase in 2000 resulted from increased interest income earned on higher
average cash balances as a result of funds received from the sale of our
preferred stock in April 2000.
Preferred stock accretion
The adjustment to accrete the carrying amount of our convertible preferred
stock to its redemption amount increased from $341,000 in 1998 to $810,000 in
1999 to $1.5 million in 2000. These increases are related to sales of our
convertible preferred stock in those years.
Net loss applicable to common stockholders
Net loss applicable to common stockholders increased from $4.0 million in
1998 to $6.9 million in 1999 to $10.6 million in 2000. These increases in net
loss were primarily attributable to expanding our product development efforts,
increases in personnel and marketing expenses incurred relating to the
introduction of Serenade and the adjustments to accrete the carrying amount of
our preferred stock to its redemption amount.
Income taxes
As of December 31, 2000, we had net operating loss carryforwards of
approximately $21.5 million for federal and state income tax purposes that
expire in the years 2010 through 2020 and 2003 through 2010, respectively. We
also had approximately $322,000 and $360,000 in federal and state income tax
credits, respectively, which expire in the years 2010 through 2020. Future
utilization of the our net operating loss and other credit carryforwards may be
subject to limitations set forth in the Internal Revenue Code and similar state
provisions. These limitations could result in the expiration of the net
operating losses before utilization.
Liquidity and Capital Resources
Since our inception, we have financed our operations primarily through
private sales of our equity securities, resulting in gross proceeds of $39.2
million through June 30, 2001. To a lesser extent, we have financed our
operations and other capital requirements through borrowings. As of December
31, 2000, we had cash and cash equivalents of $12.5 million and working capital
of $13.4 million. As of June 30, 2001, we had cash and equivalents of $6.4
million and working capital of $7.9 million.
Net cash used in our operating activities was $3.4 million in 1998, $5.9
million in 1999, $10.2 million in 2000, and $5.0 million for the six months
ended June 30, 2001. Net cash used in operating activities resulted primarily
from net losses for those periods.
27
Net cash used in investing activities was $701,000 in 1998, $1.l million in
1999, $2.4 million in 2000 and $780,000 for the six months ended June 30, 2001.
Investing activities consisted of the purchase of plant and equipment.
Net cash provided by financing activities was $6.3 million in 1998, $6.9
million in 1999 and $22.2 million in 2000. Net cash provided by financing
activities was primarily from the sale of preferred stock and proceeds from
long-term borrowings, net of repayments. Net cash used in financing activities
was $390,000 for the six months ended June 30, 2001 primarily for the repayment
of notes payable and capital lease obligations and prepaid financing costs.
As of December 31, 2000, aggregate principal payments required under notes
payable and capital lease obligations totaled $5.7 million. These payments are
payable through 2003. We financed a portion of the purchase of our
manufacturing facility in Tlaxcala, Mexico with a $5.0 million limited recourse
promissory note from the seller. This note is due upon the receipt of proceeds
from this offering.
Our 10-year facilities lease for office, laboratory and pilot plant space in
Davis, California provides for minimum lease payments of approximately $194,000
per year which commenced upon completion of construction in March 1999.
As of June 30, 2001, we had capital equipment of $10.6 million less
accumulated depreciation of $728,000 to support our research, development,
manufacturing and administrative activities. For the twelve months subsequent
to June 30, 2001 we expect to incur capital expenditures of approximately
$10.0 million as we acquire equipment and expand and upgrade our facilities.
Our capital requirements depend on numerous factors, including market
acceptance of our products and the resources we devote to develop and support
our products. We expect to devote substantial capital resources to expand our
sales and marketing capabilities, expand our research and development
activities, enhance our manufacturing facilities and for working capital and
other general corporate purposes. These additional expenses and expenditures
will consume a material amount of our cash resources, including a portion of
the net proceeds of this offering. We believe that the net proceeds from this
offering, together with our existing cash balances, will be sufficient to fund
our currently foreseeable liquidity requirements for the next twelve months. We
may, however, need to raise additional capital, which may not be available on
terms acceptable to us, if at all.
Quarterly Results of Operations
Our operating results for a particular quarter or year are likely to
fluctuate, which could result in uncertainty surrounding our level of earnings
and possibly a decrease in our stock price. Numerous factors will contribute to
the unpredictability of our operating results. In particular, our sales are
expected to be highly seasonal. Sales of pest management products for the
agricultural market are dependent on planting and growing seasons, climate
conditions and other variables, which we expect to result in substantial
fluctuations in quarterly sales and earnings. In addition, most of our
expenses, such as employee compensation and lease payments for facilities and
equipment, are relatively fixed. Our expense levels are based, in part, on our
expectations regarding future sales. As a result, any shortfall in sales
relative to our expectations could cause significant changes in our operating
results, including the size and timing of significant distributor and grower
transactions, the delay or deferral of customer use of Serenade or our future
products and the fiscal or quarterly budget cycles of our customers. For
example, customers may purchase large quantities of our products in a
particular quarter to store and use over long periods of time, or time their
purchases to coincide with their receipt of revenue or loan periods, which may
cause significant fluctuations in our operating results for a particular
quarter or year.
28
Quantitative and Qualitative Disclosures About Market Risk
The primary objective of our investment activities is to preserve principal
while at the same time maximizing the income we receive from our investments
without significantly increasing risk. Some of the securities that we invest in
may have market risk. This means that a change in prevailing interest rates may
cause the principal amount of the investment to fluctuate. For example, if we
hold a security that was issued with a fixed interest rate at the then-
prevailing rate and the prevailing interest rate later rises, the principal
amount of our investment will probably decline. To minimize this risk in the
future, we intend to maintain our portfolio of investments in a variety of
securities, including commercial paper, money market funds and government and
non-government debt securities. The average duration of all of our investments
as of December 31, 1999 and 2000 and June 30, 2001 was less than 90 days. Due
to the short-term nature of these investments, we believe that we have no
material exposure to interest rate risk arising from our investments.
Recent Accounting Pronouncements
In June 1998, the Financial Accounting Standards Board issued Statement No.
133, "Accounting for Derivative Instruments and Hedging Activities," or SFAS
133 which, as amended, is required to be adopted in years beginning after June
15, 2000. Because we do not use derivative instruments, the adoption of SFAS
133 did not have an effect on our results of operations, financial position or
cash flows.
In July 2001, the FASB issued Statements of Financial Accounting Standards
No. 141, "Business Combinations," or SFAS 141 and No. 142, "Goodwill and Other
Intangible Assets," or SFAS 142. SFAS 141 requires that the purchase method of
accounting be used for all business combinations initiated after June 30, 2001.
Use of the pooling-of-interests method is no longer permitted. SFAS 141 also
includes guidance on the initial recognition and measurement of goodwill and
other intangible assets acquired in a business combination that is completed
after June 30, 2001. SFAS 142 no longer permits the amortization of goodwill
and indefinite-lived intangible assets. Instead, these assets must be reviewed
annually (or more frequently under certain conditions) for impairment in
accordance with this statement. Intangible assets that do not have indefinite
lives will continue to be amortized over their useful lives and reviewed for
impairment in accordance with existing guidance. We are required to adopt SFAS
142 effective January 1, 2002. Because we have historically not been party to
any business combinations and therefore have not recorded related goodwill and
intangible assets, the adoption of SFAS 141 and SFAS 142 did not and is not
expected to have an effect on our results of operations, financial position or
cash flows.
29
BUSINESS
Overview
We are a biotechnology company focused on leveraging our proprietary
technology platform to discover, develop, manufacture and market effective,
safe and environmentally friendly natural pest management products for the
agricultural and institutional and home markets. Our proprietary technology
platform consists of our microorganism database, screening technology and
natural product compound library and enables us to discover and characterize
naturally occurring microorganisms that we believe can be developed into
natural product solutions to almost any pest or plant disease. We are
developing and commercializing a pipeline of natural pest management products,
including our first product, Serenade, which we believe will offer superior
alternatives to synthetic chemical pesticides and genetically modified crops
for conventional and organic growers.
Using our proprietary technology platform, we isolate and screen naturally
occurring microorganisms in a highly efficient manner to identify those that
may have novel, effective and safe pest management characteristics. We then
employ natural product chemistry to analyze and characterize the compound
structures of selected microorganisms to identify product candidates for
further development and commercialization. To date, we have screened more than
17,000 microorganisms, which has enabled us to identify 23 product candidates
that display high levels of activity against insects, nematodes and plant
diseases. These include Serenade, a biofungicide, and our most advanced product
candidates, Sonata, a biofungicide, Virtuoso, a bioinsecticide, and Vivace, an
enhancer of Bt, the world's most widely-used biopesticide. We believe that
Serenade and each of these three initial product candidates can compete
favorably with existing pest management products because they:
. are highly effective;
. offer growers an attractive value proposition in terms of cost-effective
plant disease and pest control, resulting in increased yields;
. have an accelerated time-to-market;
. increase food and worker safety and reduce the risk of negative
environmental impact;
. address the rapidly growing organic foods market; and
. reduce the risk of pest resistance.
We began selling Serenade in the United States in July 2000. On the basis of
over 750 field trials, Serenade has generally proven to be as or more effective
than synthetic chemical pesticides on a wide variety of plant diseases.
Serenade is currently approved for use on high-value specialty crops, such as
grapes, apples, pears, cherries, tomatoes, hops, several vegetables, peanuts
and walnuts, and for home and garden uses, and we are seeking or plan to seek
approval for other crops, such as bananas, citrus, turf and ornamentals. A
formulation of Serenade is approved for use in organic agriculture, which
allows us to address this increasingly important and rapidly growing market.
We believe that our proprietary technology platform will be the foundation
for the discovery and development of natural products for the pest management
industry. We also believe that our proprietary technology platform has broad
commercial applications beyond pest management, including animal health, human
health and pharmaceutical, aquaculture, industrial enzyme and specialty
chemical applications. We intend to continue establishing strategic
collaborations with chemical, biotechnology, pharmaceutical and consumer
products companies to support the development and commercialization of natural
products for pest management and other applications. To date, we have entered
into strategic collaborations with Dow AgroSciences LLC, Maxygen, Inc., Dragoco
Gerberging & Co. AG and American Home Products Corporation.
30
Industry Background
Crop Protection
Growers are constantly challenged to supply the increasing global demand for
food, while reducing the negative impact of crop protection practices on
consumers, farm workers and the environment. According to the Food and
Agriculture Organization of the United Nations, global crop losses from pests,
including bacterial, fungal and viral plant diseases, nematodes, insects and
weeds, are estimated at $240 billion annually. Growers have historically relied
on traditional practices such as cultivation, crop rotation and plant breeding
to protect their crops. Although most growers currently rely on synthetic
chemical pesticides for crop protection, an increasing number are integrating a
combination of traditional practices with synthetic chemical pesticides,
genetically modified crops and natural pest management products into a system
called integrated pest management. Due to recent technological advances in
natural pest management products and increasing environmental, food and worker
safety concerns relating to synthetic chemical pesticides and genetically
modified crops, natural pest management products are becoming an increasingly
important component of the integrated pest management solution.
Synthetic Chemical Pesticides
According to Wood MacKenzie, consultants to the agricultural biotechnology
sector, in 2000, approximately $30 billion was spent globally on synthetic
chemical pesticides. Of this amount, approximately $11 billion was spent to
protect high value specialty crops and turf and for home and garden uses, while
the remainder was spent to protect large acreage row crops, according to
Industrieverband Agrar e.V., the German Agrichemical Association. Although
synthetic chemical pesticides often are effective in controlling pests, many
are acutely toxic and are suspected carcinogens. The use of some synthetic
chemical pesticides has been shown to have harmful effects on the environment,
humans and other animals, including bees, lady beetles and other beneficial
insects. Consumers are increasingly demanding food that is free of chemical
residues and produced in an environmentally friendly manner. As a result, some
food and beverage companies such as Campbell's Soup Company, Gerber Products
Company and Kendall-Jackson Wine Estates restrict the use of several synthetic
chemical pesticides on crops for which they have contracted.
In addition, growers incur significant costs when using synthetic chemical
pesticides, including the costs of complying with required minimum waiting
periods before workers may reenter fields after spraying, limitations on
spraying in the period prior to a harvest because of chemical residues and
increased susceptibility to pest resistance. According to the National Academy
of Sciences, more than 500 pests have developed resistance to synthetic
chemical pesticides. When resistance develops, growers must increase the
quantity or frequency of pesticide applications to manage pests effectively,
which not only increases crop production costs but also increases health and
environmental risks associated with synthetic chemical pesticide use.
Concerns associated with the use of synthetic chemical pesticides, including
adverse environmental effects, food and worker safety and increasing negative
public perception, have prompted federal, local, state and foreign governments
and regulatory agencies to restrict or eliminate some uses of these pesticides.
For example, in 1996, Congress unanimously passed the Food Quality Protection
Act of 1996, which has led the EPA to limit and, in some cases, prohibit the
use of several synthetic chemical pesticides in and around schools and
households and in foods. The European Union has also enacted legislation to
reduce or restrict pesticide use.
Development and registration of new synthetic chemical pesticides is costly
due to stringent regulatory requirements. Major agrichemical companies
typically test hundreds of thousands of chemicals each year to find a single
new product that will meet these stringent regulatory requirements. According
to the American Crop Protection Association, the average cost and time to bring
a new synthetic chemical pesticide to market is now estimated to be at least
$70 million to $100 million and seven to ten years. Accordingly, major
agrichemical companies focus their product development efforts primarily on
pesticides targeted for use on large acreage row crops in an effort to recover
their substantial product development costs and achieve economies of scale. It
is often uneconomical for major agrichemical companies to develop synthetic
chemical
31
pesticides for use in the highly fragmented, specialty crop market, which
results in fewer pest management alternatives for growers in this market.
Genetically Modified Crops
Beginning in the 1980s, major agrichemical companies sought to reduce human
health risks associated with synthetic chemical pesticides by investing
billions of dollars to develop genetically modified plants that resist pests or
have high tolerance to herbicides. Grower acceptance of this technology is
evidenced by the fact that, in 2000, growers in the United States planted
approximately 78 million acres of genetically modified soy bean, cotton and
corn crops, representing approximately 49% of the aggregate acreage of these
crops planted in the United States.
Despite general acceptance by growers, consumer disapproval of genetically
modified crops, especially in Europe and Japan, threatens the future commercial
viability of this technology. In response to consumer concerns, several food
processors have demanded that their contracted growers supply them with only
non-genetically modified crops. Environmental groups have also voiced concerns
about the unintended effects of genetically modified crops, including pest
resistance, contamination of non-modified crops, allergic reactions in humans
and negative impacts on non-target species such as on soil microorganisms and
monarch butterfly populations. In addition, growers and food processors have
found it difficult and costly to segregate and track modified and non-modified
crops within the current commodity distribution system. For example, last year,
genetically modified corn approved only for use as animal feed was found in
many human foods, causing concern among consumers, food processors, regulators,
environmental groups and growers.
Some scientific experts have asserted that widespread plantings of
genetically modified crops that produce an internal pesticide could lead to the
proliferation of pests resistant to that pesticide. As pests become resistant
to pesticides produced by genetically modified crops, the effectiveness of
these crops is reduced. The U.S. Environmental Protection Agency, or the EPA,
requires companies that produce genetically modified crops to submit costly
resistance management and monitoring plans with their registration packages.
Natural Pest Management Products
The development and use of natural pest management products is increasing
rapidly in response to consumer, grower and regulatory concerns regarding
current pest management practices, pest resistance and food and worker safety.
An increasing number of growers are integrating natural pest management
products into a more sustainable approach to crop protection.
Natural pest management products include biopesticides as well as minerals
such as copper and sulfur. Biopesticides consist of or are based on a living
organism or a substance produced by a living organism, and they are generally
distinguished from synthetic chemical pesticides by their unique modes of
action, low toxicity to non-target species, biodegradability and natural
occurrence.
The EPA classifies biopesticides as microbials or biochemicals. Microbial
pesticides contain a microorganism such as a bacterium or fungus as the active
ingredient. The most widely used microbial pesticides are various types of the
bacterium Bacillus thuringiensis, or Bt, which can control specific insects in
vegetables and other crops. Biochemical pesticides are naturally occurring
substances that control pests by non-toxic mechanisms. Biochemicals include
products that interfere with a pest's growth or mating patterns such as
pheromones and plant growth regulators that increase crop yield.
While only about 1% of annual global crop protection expenditures are
attributable to natural pest management products, the use of these products is
increasing rapidly. For example, according to the California Department of
Pesticide Regulation from 1991 to 1999, biopesticide use in California, the
state with the largest production of fruits and vegetables, increased at a
compound annual growth rate of over 25%. Historically, biopesticide market
share has been limited by the perceived relative lack of effectiveness,
difficulty in
32
application, constraints in the timing of application and shorter shelf life as
compared to synthetic chemical pesticides. We believe that recent advances in
biopesticides will continue to overcome these perceived deficiencies and will
greatly increase their adoption.
Organic Food
In order to be certified as organic, food must be produced and processed
without the use of synthetic chemicals, bioengineering or any other
adulteration. Accordingly, organic growers have few pest management
alternatives, other than traditional practices and natural pest management
products. Consumer demand for organically grown food has been increasing
rapidly. We believe this is principally due to concerns about food safety and
the adverse environmental effects of synthetic chemical pesticides and
genetically modified crops. In the United States, sales of organically grown
food have grown at a compound annual growth rate of more than 20% over the last
decade, resulting in an estimated $6.6 billion in sales during 2000. In late
2000, the U.S. Department of Agriculture approved national production and
labeling standards for organic food marketed in the United States. These
standards are widely expected to facilitate the continued growth of the organic
foods industry. Large food processors and agricultural businesses, such as Dole
Food Company, General Mills, Inc., H.J. Heinz Company, Kellogg Company and
Gerber Products Company, have entered the organic foods market due to its
attractive profit margins and growth potential.
Institutional and Home Pest Management
Approximately $2.2 billion is spent annually worldwide on synthetic chemical
pesticide products to control pests such as cockroaches, flies and mosquitoes
in the institutional market, including in and around schools, parks, golf
courses and other public use areas. Homeowners spend approximately $5.0 billion
annually worldwide on pest management products to control pests in their homes,
gardens and lawns and to control fleas and ticks on their pets. Producers of
livestock such as cattle, swine and poultry use pest management products to
control pests and parasites. The Food Quality Protection Act of 1996 has led to
the reduction in use or elimination of some synthetic chemical pesticides,
including in and around schools and households. Several states and
municipalities have restricted pesticide use in and on public use areas.
Congress is also considering new legislation to promote school pest management
practices that minimize risk to children and provide safety information to
parents and school staff when pesticides are used in schools. Homeowners are
becoming increasingly concerned about the dangers to their children and pets of
spraying synthetic chemical pesticides in their homes and gardens. As a result,
institutional and home uses present opportunities for new effective, safe and
environmentally friendly natural pest management products.
The AgraQuest Solution and Advantages
We believe growers and other pesticide users seek pest management products
that are effective, competitively priced, safe and environmentally friendly. We
are developing and commercializing a pipeline of natural pest management
products, including Serenade, which we believe will offer superior alternatives
to synthetic chemical pesticides and genetically modified crops in terms of
performance, value, safety and environmental impact.
We have developed a proprietary technology platform, consisting of a
microorganism database, a screening technology and a natural product compound
library, which we believe will provide the foundation for the discovery and
development of natural products for the pest management industry. We also
believe our technology platform can be used to develop products for broader
applications, including animal health, human health and pharmaceutical,
aquaculture, industrial enzymes and specialty chemicals.
33
Our Proprietary Technology Platform
Our proprietary technology platform has the following advantages:
. Highly efficient discovery process. We believe we can discover new
effective product candidates faster than other developers of pest
management products. Our first product, Serenade, was discovered after
testing only 713 microorganisms. Major agrichemical companies typically
test hundreds of thousands of chemicals each year to discover a single
new product. To date, we have identified 23 product candidates from the
more than 17,000 microorganisms in our database. We believe these
product candidates can compete with synthetic chemical pesticides on
performance, cost-effectiveness, shelf life and ease of use.
. Valuable data capture and utilization. Our proprietary technology
platform allows us to gather data on the source of each microorganism,
taxonomy, activity spectrum and the natural product compounds produced
by the microorganism. Using this information, we are able to determine
which microorganisms may have the highest pest management commercial
potential. Expanding the information in our microorganism database and
natural product compound library improves the efficiency of our product
discovery process. This information may also be valuable to chemical,
biotechnology, pharmaceutical and consumer products companies for
developing natural products for their respective industries.
. Cost-effective and rapid new product development. We believe we can
bring effective natural pest management products to market at greater
speed and cost efficiency than our competitors. For example, we spent
approximately $6 million for the testing, initial development and
approval process for Serenade. The cost to bring a new synthetic
chemical pesticide or genetically modified crop to market is estimated
to be at least $70 million to $100 million.
Serenade and Our Initial Product Candidates
Serenade and our three initial product candidates:
. Are highly effective. Laboratory and field trials suggest that Serenade
and our initial product candidates are generally more effective than
existing biopesticides and generally are as or more effective than
synthetic chemicals in controlling targeted pests. These trials also
demonstrate that Serenade and Sonata generally have a broader disease
control spectrum than synthetic chemical pesticides.
. Offer growers an attractive value proposition. We believe by using
Serenade and our future natural pest management products, growers can
increase profits while increasing food and worker safety and reducing
environmental impact. Serenade is easy to use, competitively priced and
has a comparable shelf life to synthetic chemical pesticides. In
addition, the naturally low toxicity of Serenade allows growers to
utilize it safely up to the time of harvest, limiting crop losses caused
by the late onset of plant diseases.
. Have an accelerated time-to-market. By combining our proprietary
technology platform and the favorable regulatory approval process for
biopesticides, we have the ability to navigate our products quickly
through the development and regulatory approval processes. For example,
we were able to receive conditional EPA approval for Serenade within
approximately 38 months from the time we first tested the Serenade
strain. Conversely, it typically takes approximately seven to ten years
to develop and obtain regulatory approval for a synthetic chemical
pesticide or genetically modified crop.
. Increase safety and reduce risk to the environment. We believe Serenade
and our initial product candidates offer a favorable alternative to
synthetic chemicals and genetically engineered crops, which have come
under heightened scrutiny due to the negative environmental impact and
health risks associated with their use. Our product and product
candidates are based on naturally occurring microorganisms that we
select specifically for their safety and that leave no synthetic
chemical residues, increasing food safety. Based upon extensive field
trials and independent toxicology studies and risk
34
assessments, we believe that Serenade and Sonata offer improved safety for
growers, workers, consumers and the environment.
. Provide unique solutions for organic crops. We believe Serenade and our
initial product candidates will be of particular benefit by providing
organic growers, who have a limited toolbox of crop protection
solutions, with a means to grow their crops more productively.
. Have novel and complex modes of action that reduce the risk of pest
resistance. Pest resistance concerns provide growers with strong
motivation for growers to incorporate Serenade and our initial product
candidates into their integrated pest management programs. Due to strict
regulatory requirements, some synthetic chemical pesticides rely on a
single mode of action and are therefore subject to an increased
probability of pest resistance. Similarly, genetically modified crops
typically contain a single active gene and are also subject to an
increased probability of pest resistance. Conversely, biopesticides
typically rely on novel and complex modes of action that are more
difficult for pests to develop resistance to. We therefore believe that
growers can allocate a large portion of their total pesticide use to our
natural pest management products without compromising the risk of pest
resistance in their fields.
. Are produced by environmentally friendly and sustainable production
processes. Unlike the production of synthetic chemical pesticides, which
requires large volumes of synthetic chemicals and solvents, our products
are produced by fermentation using readily available agricultural raw
materials such as soy flour and corn starch. Our production process is
not only less harmful to the environment than that of synthetic chemical
pesticides but also provides farmers with an additional sales channel for
their products.
Our Strategy
Our goal is to become the leader in the discovery, development and
commercialization of natural pest management products. The key elements of our
strategy include:
. Utilize our proprietary technology platform to identify new product
candidates. We intend to increase our natural pest management product
offerings by identifying new product candidates discovered using our
proprietary technology platform. By applying our proprietary screening
technology to our microorganism database and utilizing our natural
product compound library, we anticipate that we will continue to
discover multiple natural pest management product candidates annually.
. Increase sales of Serenade. We have initiated marketing activities
designed to increase the distribution and sale of Serenade. We intend to
expand our distribution arrangements with established agrichemical
distributors and retailers in order to leverage their existing sales
forces and grower relationships. We also intend to expand our team of
field development specialists to maintain close relationships with
growers and educate industry leaders and distributors. As we obtain
regulatory approvals, we plan to launch Serenade in key foreign markets,
including Australia, Canada, Europe, Japan, New Zealand and South and
Central America. We are seeking to add additional crops to the permitted
uses of Serenade in Chile and the United States, and we may expand the
use of Serenade to large acreage row crops.
. Develop and commercialize product candidates. We will continue to
allocate significant research and development resources to develop and
commercialize new natural pest management products that we have
identified using our proprietary technology platform. To date, we have
identified 23 product candidates, including Sonata, Virtuoso and Vivace,
which each display high levels of activity against insects, nematodes
and plant diseases. We initially intend to focus our research and
development efforts on Sonata, Virtuoso and Vivace, all of which we
believe can compete favorably with existing pest management products on
efficacy, cost-effectiveness, pest resistance, shelf life, ease of use,
food and worker safety and environmental impact. We may also establish
strategic collaborations with third parties to support the development
and commercialization of those natural pest management product
candidates that we choose not to develop internally. We will maintain
control over product quality, consistency and margins by manufacturing
our products at our facility in Tlaxcala, Mexico.
35
. Focus initially on high-value specialty crops. We are focusing our
initial commercialization efforts on high value specialty crops in the
United States, such as grapes, apples, pears, tomatoes, vegetables, nuts
and ornamentals. We expect growers of high-value specialty crops to
derive the greatest economic benefit from our natural pest management
products, in terms of relative cost, safety and the value of the
expected yield increases.
. Maximize organic market opportunities. To address the rapidly growing
organic market, in which there are few pest management alternatives, we
will continue to ensure that a formulation of each of our products meets
the requirements for organic food production in our target, specialty-
crop markets. We also intend to conduct field trials in large acreage
organic crops, such as cereals, which are well suited for our products
but have less competition than conventional large acreage crops.
. Brand AgraQuest as the leading provider of natural pest management
solutions. We believe that building our corporate brand will foster
continued adoption of our natural pest management products by
establishing AgraQuest as a leading supplier of effective, safe and
environmentally friendly natural pest management products with
significant benefits over existing pest management solutions. We also
believe that strong brands will increase strategic collaboration
opportunities, contributing to potential revenue growth and
diversification. To enhance industry and public awareness of our company
and increase demand for our natural pest management products, including
Serenade, we intend to pursue an aggressive brand development strategy
through targeted advertising, conference and trade show appearances,
promotions and public relations.
. Leverage our proprietary technology platform in conjunction with
strategic collaborators. We intend to pursue strategic collaborations
with chemical, biotechnology, pharmaceutical and consumer products
companies to use our proprietary screening technology and microorganism
database to develop products for use in pest management, as well as
animal health, human health and pharmaceuticals, aquaculture, industrial
enzymes and specialty chemicals. Strategic collaborations will allow us
to enhance our market presence and visibility and have the potential to
generate significant revenues.
. Pursue select acquisitions. We may invest in or acquire businesses,
technologies or products that we believe would strategically complement
our business and allow us to be a more complete provider of crop
production solutions.
36
Our Proprietary Technology Platform
Our proprietary technology platform consists of three key components: a
microorganism database, screening technology and a natural product compound
library. Our proprietary technology allows us to quickly and accurately
identify microorganisms with the greatest pest management commercial potential.
To date, we have identified 23 product candidates from the more than 17,000
microorganisms in our database that display high levels of activity against
insects, nematodes and plant diseases.
Our product candidates are discovered and developed through the following
steps:
[A flow chart diagram describing our product candidate discovery and
development processes, including the following text:
DISCOVERY
. Collection and Isolation (sourcing and isolation of microorganism)
. Fermentation (produce sufficient testing quantities; maximize pesticidal
properties; mimic commercial media)
. Primary Screening (test and confirm pesticidal activity and dose response)
. Preliminary Toxicology (test for toxic effects)
. Natural Product Chemistry (compare natural compounds produced by each
selected microorganism with compounds in our natural product compound
library; perform stability studies: pH, temperature; identification,
purificaton and structure elucidation of active compounds
. Pre-Development Testing
PRODUCT DEVELOPMENT
. Process Development and Formulation
. Advanced Toxicology
. Commercial Development
. Field Testing]
37
Discovery
. Collection and isolation. We use information from our existing
microorganism database such as taxonomic groups, geographical locations,
types of samples, niches and habitats to collect and identify new
microorganism samples that may have novel, effective and safe pest
management characteristics. We then isolate these selected
microorganisms on proprietary media.
. Fermentation. Before testing the selected microorganisms for activity
against pests, we first ferment them to produce sufficient quantities
for testing. We grow the selected microorganisms in proprietary media,
which maximizes their pesticidal properties. In addition, we have
developed several proprietary fermentation processes that are designed
to replicate those that would be required for large-scale fermentation
and commercial production and, therefore, we avoid the time and expense
of an unsuccessful scale-up.
. Primary screening. We use automated, miniaturized biological assays to
test the selected microorganism's effectiveness against several insect,
mite and nematode pests and plant diseases. We compare those results to
synthetic chemical pesticide standards. When a microorganism shows a
high level of pesticidal activity, we conduct further tests to determine
the spectrum of activity, mode of action, stability and activity on
plants.
. Natural product chemistry. Using high-performance liquid chromatography
with diode array detection technology, we compare the natural product
compounds produced by each of the selected microorganisms with the
compounds in our natural product compound library. This allows us to
eliminate those microorganisms that produce known toxins and select
those that we believe are novel and safe. From the selected
microorganisms, we identify and characterize the natural product
compounds responsible for their pesticidal activity by using high
performance liquid chromatography, liquid chromatography-mass
spectroscopy and nuclear magnetic resonance equipment.
. Pre-development testing. We conduct laboratory, greenhouse and initial
small plot field tests to select product candidates for further
development.
Product Development
. Development of the manufacturing process. We have developed proprietary
processes that increase the yield of both the microorganism and the
natural product compounds produced by the microorganism during
fermentation. We have developed proprietary methods for producing and
analyzing these compounds, which results in greater product consistency
and efficacy than biopesticides produced using conventional techniques.
We believe that our process development allows us to produce products
that have superior performance and lower cost than existing
biopesticides and have comparable or better performance than synthetic
chemical pesticides. We then scale up these proprietary processes in
progressively larger fermentation tanks.
. Formulation. We are able to develop proprietary wettable powder, liquid
and granule formulations that allow us to tailor our products to our
customers' needs. This allows us to develop product formulations with
enhanced performance characteristics, such as effectiveness, value,
shelf life, suitability for organic agriculture, dispersibility,
wettability, rainfastness, compatibility with other pest management
products and ease of use.
. Field testing. We conduct hundreds of field trials for each product
candidate that we develop. These field trials are conducted in small
plots on commercial farms or research stations by our own field
development specialists and private and public researchers to determine
large-scale effectiveness, use rates, spray timing and crop safety. We
conduct field trials globally in both hemispheres to accelerate the
results of our field trials and provide alternate season learning
opportunities. As the product candidate nears commercialization, we
conduct demonstration trials in conjunction with our sales and marketing
team. These trials are conducted with distributors, influential growers
and food processors on larger acreages in a commercial setting.
38
Serenade and Our Initial Product Candidates
The following table sets forth information relating to Serenade and our
initial product candidates that are most advanced in development:
Primary Modes
Product Name Uses of Action Target Markets Regulatory Status
Serenade Controls many Attacks fungal Registered for Registered in
bacterial and spores and use on specialty the United
fungal plant bacteria as they crops, including States,
diseases germinate; apples, pears, Chile, Mexico
excretes grapes, and Puerto Rico;
antifungal cherries, approved for use
compounds; tomatoes, hops, in 49 U.S.
competes for several states; filed
space and food vegetables, registration
on the plant's peanuts and packages in the
surface walnuts, and for European Union,
home and garden; Argentina,
also targeting New Zealand and
bananas, Switzerland
ornamentals and
turf
---------------------------------------------------------------------------------------
Sonata Controls many Prevents spore Specialty crops, Technical and
fungal and some germination on cereals, experimental use
bacterial plant's surface; ornamentals and permit
diseases; excretes home and garden registrations
complementary to antifungal submitted to the
Serenade compounds EPA and the
California EPA
---------------------------------------------------------------------------------------
Virtuoso Controls Possibly Specialty crops, In development;
caterpillar inhibits cell turf, home and registration not
pests; fleas, growth in garden, and row yet submitted to
some flies and caterpillar crops; animal the EPA
mites pests health, pets
---------------------------------------------------------------------------------------
Vivace Enhances the Increases the Specialty crops, In development;
activity of Bt effect of Bt in home and garden registration not
bioinsecticide; destroying the yet submitted to
complementary to stomach lining the EPA
Virtuoso of insects
Serenade
We believe that Serenade is the first and only biofungicide that is
effective on a wide variety of plant diseases. Serenade is based on a novel and
patented strain of Bacillus subtilis, which we isolated using our proprietary
screening technology. Bacillus subtilis bacteria are known to be non-toxic and
not harmful to animals. We began marketing Serenade commercially in the United
States in July 2000. Serenade currently is targeted for use on high value
specialty crops and is registered for use on apples, pears, grapes, cherries,
tomatoes, hops, several vegetables, peanuts and walnuts. We are seeking to
expand the permitted uses of Serenade to other specialty crops, turf and
ornamentals. Serenade is currently formulated as a wettable powder and a
wettable disbursable granule that is topically applied either independently or
in conjunction with traditional pesticides. We believe Serenade has the
following advantages:
. High level of broad spectrum activity against many bacterial and fungal
plant diseases;
. Can be integrated into pest management programs for both conventional
and organic growers;
. Improved safety for the environment, applicators and farm workers;
39
. Can be sprayed up until harvest and does not require any special
handling or equipment;
. No synthetic chemical residues, enhancing food safety; and
. Reduced likelihood of pest resistance due to its novel and complex mode
of action.
To address the rapidly growing organic market, we have developed and
registered with the EPA a formulation of Serenade that is included on the
Organic Materials Review Institute's list of approved products. Additionally,
we have in-house capabilities to develop other formulations of Serenade that
specifically address market needs and customer preferences. For example, we are
currently developing Rhapsody, a formulation of Serenade targeted for
ornamental flowers and foliage.
We believe Serenade offers an attractive value proposition to the grower in
terms of cost effective plant disease control resulting in increased yields
compared to synthetic chemical pesticides. For example, field trials conducted
by our customers, the University of Arizona and our own field development
specialists to determine the effectiveness of Serenade in controlling
Sclerotinia, a major lettuce disease, indicated that Serenade was on average 8%
more effective than the leading chemical in controlling Sclerotinia, which
implies increased lettuce yields of on average 31%.
Serenade has been tested in more than 750 field trials in the United States
and 16 other countries worldwide. In addition to conducting our own field
trials, we have also conducted field trials with major growers, universities
and consultants in order to further validate the performance of Serenade. The
compiled field data shows that Serenade is generally as or more effective than
synthetic chemical pesticides in preventing a broad spectrum of diseases, such
as: botrytis bunch rot/gray mold, powdery mildews, fire blight, bacterial spot,
Sclerotinia rots/blights and black sigatoka. Of particular interest is
Serenade's control of fire blight, lettuce drop and tomato bacterial spot for
which growers have limited alternatives.
In addition to field trials, we also have conducted numerous laboratory and
greenhouse experiments. Laboratory and greenhouse experiments show that
Serenade works effectively on brown rot in stone fruits such as peaches and
almonds and gray mold in strawberries. Laboratory studies and field
observations also show that Serenade has curative activity on powdery mildew;
unlike most pesticides, it was shown to control the disease after the disease
was already present. These potential applications of Serenade are being tested
more fully in research field trials.
Serenade received registration approval for Chile in October 1999, in the
United States in June 2000, and in Mexico in July 2001. We are currently
seeking regulatory approval for Serenade in the European Union, Costa Rica,
Argentina, New Zealand, Switzerland, Japan, Australia, South Africa and Canada.
In October 2000, we received notice that our Serenade registration package
passed the completeness check by the Commission of the European Communities,
Director General of Agriculture, and we have commenced national registrations
in the European Union.
Sonata
Sonata is based on a novel and patented strain of Bacillus pumilus, which we
isolated using our proprietary screening technology. Bacillus pumilus bacteria
are known to be non-toxic and not harmful to animals. Our strain of Bacillus
pumilus has a unique, high level of broad spectrum activity against many fungal
and some bacterial plant diseases. Laboratory, greenhouse and more than 60
field trials indicate that Sonata is particularly effective against downy
mildews, powdery mildews, rusts, Sclerotinia blights/rots and some bacterial
diseases.
We believe that Sonata is as or more effective, safer and more
environmentally friendly than many synthetic chemical pesticides. In addition,
while their complex modes of action make it unlikely that product resistance
will develop even when used alone, Serenade and Sonata can be rotated or
combined with each other or with other pest management products to reduce the
likelihood of pest resistance. Growers usually prefer to use multiple products
for disease control and typically rotate or tank mix several pest management
products within a growing
40
season. Sonata's complementary nature addresses growers' desire to avoid
reliance on a single product, reduces the likelihood of resistance development
and obtains the best spectrum of disease control.
We submitted the technical registration for Sonata to the EPA in May 2000.
An experimental use permit that would allow sales on 4,000 acres of some crops
was submitted to the EPA and the Department of Pesticide Regulation of the
California Environmental Protection Agency in November 2000.
Virtuoso
Virtuoso is based on a novel and proprietary strain of Streptomyces, which
we tested using our proprietary screening technology. This strain, which was
licensed exclusively to us for an indefinite term in 1998, has broad spectrum
control of caterpillar pests, such as armyworms, codling moths, cotton
bollworms and budworms, cabbage loopers and diamondback moths, and it also has
activity on fleas, some flies and mites.
We believe Virtuoso will be an effective replacement for toxic insecticides
such as organophosphates for caterpillar pests. Organophosphates are being
restricted by the EPA under the Food Quality Protection Act. In addition, there
are major caterpillar pests affecting most of the crops we are targeting with
Serenade and Sonata, and Virtuoso would allow us to offer growers of these
crops both plant disease and insect control products. Laboratory tests and
initial field trials indicate that Virtuoso is generally as effective as
synthetic chemical pesticides in controlling some types of pests. Independent
laboratory and initial field studies conducted by four major agrichemical
companies indicated that Virtuoso has a high level of broad spectrum activity
against caterpillar pests. We also believe Virtuoso has applications in the
animal health and pet markets because of its activity on fleas and some flies.
Vivace
Vivace is a proprietary and novel suite of natural product compounds that we
isolated from a microorganism using our proprietary screening process. Vivace
is an early stage product candidate that has been shown to substantially
enhance the activity of Bt, which has provided caterpillar pest control for
conventional and organic growers for many years. Bt protein genes have been
engineered into crop plants and commercialized for caterpillar pest control in
cotton and corn. However, Bt sprays and Bt crops are not as effective as
synthetic chemical pesticides on some caterpillar pests, such as armyworms. Our
studies have shown that Vivace improves the activity of Bt by up to tenfold
such that caterpillar pest control generally equals that of synthetic chemical
pesticides. Vivace has no insecticidal activity by itself, and is effective
against caterpillar pests only in combination with Bt. Vivace's and Virtuoso's
complementary natures address growers' desire to avoid reliance on a single
product, reduce the likelihood of resistance development and obtain the best
spectrum of disease control. We intend to position Vivace and Virtuoso for use
together in integrated pest management systems for the specialty crop, turf and
home and garden markets.
Sales, Marketing and Distribution
We have initiated marketing activities designed to promote sales of Serenade
and our future natural pest management products by implementing the following
strategies:
. Target early adopters of new pest management technologies. We intend to
target large commercial growers in the United States, who generally set
industry standards through early adoption of new pest management
technologies. We plan to continue to recruit leading growers and their
consultants to participate in field trials, enabling them to become
familiar with our natural pest management products and to experience
their benefits firsthand.
. Educate growers about the benefits of our natural pest management
products. We will continue to perform on-farm demonstrations and provide
field data packages to support and validate our product claims. We will
also continue to participate in trade shows and conferences to educate
growers and their licensed pest control advisors about the benefits of
our natural pest management products.
41
. Enhance distribution relationships. We will continue using established
agrichemical distribution channels to distribute Serenade and our future
products. We intend to provide distributors a portfolio of products with
attractive profit margins and growth potential. In addition, we will
continue to provide distributors access to innovative alternative pest
management solutions, which we believe will reduce their dependence on
major agrichemical companies.
. Develop and leverage relationships with key industry influencers. We
will continue to develop relationships early in the product development
process with influential members within our target markets, including
technical experts at leading agricultural universities, licensed pest
control advisors, wineries, baby food manufacturers and other food
processors and produce packers. We believe that educating industry
influencers about the benefits of Serenade and our future products
increases the likelihood that they will recommend our products to their
growers and customers.
We have signed agreements to distribute Serenade in the United States with
leading agricultural distributors United Agri Products, Western Farm Services
and Wilbur Ellis, and in Chile with Moviagro, a Monsanto joint venture. These
distribution agreements are terminable by either party on minimal notice,
typically 30 days, and do not require the distributors to purchase any of our
products. We also have arrangements to develop and distribute Serenade in Japan
through SDS Biotech, Japan's largest supplier of biopesticides, and in France
with Agtrol. We have a one-year agreement to sell Serenade to consumers through
Gardens Alive!, a leading home and garden catalog retailer.
We currently have ten employees dedicated to sales and marketing in the
United States organized into eight geographic sales territories. We anticipate
adding additional sales and marketing personnel in the United States and in
international territories.
Strategic Collaborations
We have entered into, and will continue to pursue, strategic collaborations
with chemical, biotechnology, pharmaceutical and consumer products companies to
support the development and commercialization of natural pest management
product candidates identified through our proprietary technology platform. The
terms of strategic collaborations that we undertake depend on the nature and
stage of development of the particular product candidate. For example, for
product candidates in early stages of development, we may grant a third party
the commercial rights to that product candidate in exchange for our use of that
party's research, development or marketing resources. We also intend to license
our microorganism database for applications beyond pest management, including
the discovery and development of natural products for animal health, human
health and pharmaceutical, aquaculture, industrial enzyme and specialty
chemical products. We believe that these strategic collaborations will allow us
to maximize the potential value and reinforce the credibility of our
proprietary technology platform, as well as enhance our market presence and
revenue growth.
We have entered into the following strategic collaborations:
Dow AgroSciences. In October 2000, we entered into a research and
development agreement with Rohm and Haas Company, the agricultural business of
which was subsequently acquired by Dow AgroSciences LLC. Under this agreement,
Dow AgroSciences has the exclusive, worldwide rights to commercialize seven of
our product candidates for all uses other than human health, animal health and
aquaculture. Together with Dow AgroSciences, we will jointly review and direct
the process of identifying organisms for testing. If Dow AgroSciences selects a
product candidate for further development, it must pay us a fee, reimburse us
for our development costs relating to that product candidate and make
additional milestone payments based on the progress of product development.
Additionally, if Dow AgroSciences determines to further commercialize any of
these product candidates, it will make additional milestone payments to us, pay
the costs of EPA registration, and pay us a royalty on any product sales. In
addition, we retain a right of first refusal to manufacture these product
candidates for Dow AgroSciences for which we will receive cost reimbursements
plus a share in the profits. In November 2000, Dow AgroSciences selected its
first product candidate to develop and
42
commercialize under this agreement and began making initial milestone payments
to us. In connection with this agreement, Dow AgroSciences purchased 83,333
shares of our Series F preferred stock for $500,000.
Maxygen. In December 2000, we entered into an agreement with Maxygen, Inc.
under which we granted Maxygen a nonexclusive license to develop and
commercialize 3,000 of the more than 17,000 microorganisms in our microorganism
database for gene-shuffling uses other than for the development of
biopesticides. Maxygen has the right to select which 3,000 microorganisms it
wishes to be further developed from our database. Under this agreement, Maxygen
paid an up-front collection fee and may make future milestone payments based on
the progress of its product development and commercialization of products from
these microorganisms. The up-front collection fee is being recognized ratably
as we deliver these microorganisms to Maxygen.
American Home Products, Fort Dodge Animal Health Division. In November 2000,
we entered into an agreement with the Fort Dodge Animal Health Division of
American Home Products Corporation under which we agreed to provide it with
selected microorganisms from our microorganism database for testing and product
development. We will seek to enter into a licensing arrangement with Fort Dodge
in the event it desires to commercialize any products based on these
microorganisms.
Dragoco. In July 2001, we entered into a license agreement with Dragoco
Gerberding & Co. AG, an international supplier of perfume compositions, aroma
chemicals, cosmetic raw materials and active ingredients, under which we
granted Dragoco an exclusive license to some of our patents and other
proprietary rights to develop natural mosquito and other insect repellants.
Under this agreement, Dragoco agreed to make quarterly royalty payments based
on product sales and sublicense proceeds.
Manufacturing
To control product quality and the speed and timing of manufacturing,
protect our proprietary position in our products and lower our manufacturing
costs, we purchased a manufacturing facility in Tlaxcala, Mexico in December
2000 from Abbott Laboratories, and we recently began manufacturing Serenade at
this facility. This plant has approximately 208,000 square-feet of
manufacturing and support facilities on approximately 35 acres. We have
established comprehensive quality control and assurance procedures to ensure
that we sell high quality products. The facility includes several seed and
fermentation tanks, a downstream processing, recovery and extraction building,
several microbiology and quality control laboratories, a waste treatment plant,
warehouses and offices. We intend to add spray drying and packaging facilities
and equipment, and we expect this facility to be fully operational by the end
of 2001. We believe this facility will be adequate to meet our anticipated
manufacturing volume requirements for the foreseeable future. In addition, the
site is large enough to accommodate additional fermentation and other
processing equipment as needed.
To date, we have relied primarily on third parties to manufacture Serenade.
We have a 3,000 square-foot fermentation pilot plant in our Davis, California
facility that we use to scale up new processes and to produce material for
field trials. We intend to use a portion of the net proceeds from this offering
to expand our Davis facility.
Research and Development
We currently have 32 employees dedicated to research and development, 16 of
whom hold Ph.D. degrees. Our research and development team has technical
expertise in microbiology, natural product chemistry, entomology, plant
pathology, fermentation, product formulation and field development. In
addition, we have formed a scientific advisory board comprised of individuals
specializing in the fields of natural product chemistry, microbiology,
biochemistry and fermentation who from time to time provide our management and
scientists with specific expertise in both research and product development.
43
Our research and development activities are principally conducted at our
Davis, California facility as well as by our field development specialists on
crops in their respective regions.
We have made, and will continue to make, substantial investments in research
and development. Our research and development expenses were $3.1 million in
1998, $4.5 million in 1999, $6.3 million in 2000 and $2.7 million for the six
months ended June 30, 2001.
Intellectual Property
We rely on patents and other proprietary right protections, including trade
secrets and proprietary know-how, to preserve our competitive position. We own
19 issued U.S. patents and have two pending patent applications covering our
products, including microorganisms and natural product compounds, uses and
related technologies. Also, we own eight foreign patents and have 95 pending
foreign patent applications. We have received six trademark registrations and
have five trademark applications pending in the United States. We also have
received 93 trademark registrations and have 89 trademark applications pending
in various other countries.
We have been issued three U.S. patents for Serenade and one U.S. patent for
Sonata, covering their respective bacterial strains, compounds produced by the
strains, their formulations, use against plant pathogens and combinations with
other pesticides. These patents will expire between May 2020 and September
2021. The U.S. Patent and Trademark Office has allowed claims to compounds
produced by the novel Serenade strain. We have filed an additional U.S. patent
application for Sonata and received a notice of allowance in August 2000. If
this patent is issued, it will expire 20 years from the date of application.
We have also filed a U.S. patent application on our Virtuoso strain, the
natural product compounds produced by the strain, its formulations, its use as
an insecticide and its combination with other pesticides. Any patent that
issues will expire 20 years from the date of application.
Our success depends on our ability to operate without infringing the patents
and proprietary rights of third parties. We cannot determine with certainty
whether patents or patent applications of other parties may materially affect
our ability to make, use or sell any products. A number of crop protection and
other pest management companies, universities and research institutions may
have filed patent applications or may have been granted patents that cover
technologies similar to the technologies owned by or licensed to us.
Although we believe our patents and patent applications provide a
competitive advantage, the patent positions of crop protection and other pest
management companies are highly uncertain and involve complex legal and factual
questions. Our patents or those for which we have licensed or will license
rights may be challenged, invalidated, infringed or circumvented, and the
rights granted in those patents may not provide proprietary protection or
competitive advantages to us. We and our collaborators or licensors may not be
able to develop patentable products or obtain patents from pending patent
applications. Even if patent claims are allowed, the claims may not issue, or
in the event of issuance, may not be sufficient to protect the technology owned
by or licensed to us.
Third-party patent applications and patents could reduce the coverage of the
patents owned by or licensed to us. If patents containing competitive or
conflicting claims are issued to third parties, we may be enjoined from
pursuing commercialization of products or be required to obtain licenses to
these patents or to develop or obtain alternative products. In addition, other
parties may duplicate, design around or independently develop similar or
alternative technologies to ours or our licensors.
44
Litigation may be necessary to enforce patents issued or licensed to us or
to determine the scope or validity of another party's proprietary rights. U.S.
Patent Office interference proceedings may be necessary if we and another party
both claim to have invented the same subject matter. We may not prevail in any
of these actions or proceedings, and we could incur substantial costs and our
management's attention would be diverted if:
. litigation is required to defend against patent suits brought by third
parties;
. we participate in patent suits brought against or initiated by our
licensors;
. we initiate similar suits; or
. we participate in an interference proceeding.
Regulatory Considerations
Our activities are subject to extensive federal, state, local and foreign
governmental regulations. These regulations may prevent us or our collaborators
from developing or commercializing products in a timely manner or under
technically or commercially feasible conditions and may impose expenses, delays
and other impediments to our product development and registration efforts. In
the United States, the U.S. EPA regulates our natural pest management products
under the Federal Insecticide, Fungicide and Rodenticide Act, the Federal Food,
Drug and Cosmetics Act and the Food Quality Protection Act. Additionally, crop
protection products must be registered by the appropriate state authority
before sale in that state.
To register a crop protection product in the United States a company must
demonstrate the product is safe to humans, non-target organisms and to the
environment. To demonstrate the biopesticide's safety, required studies must be
conducted that evaluate mammalian toxicology, ecotoxicological effects to non-
target organisms and physical and chemical properties of the product.
To obtain Federal registration the company is also required to demonstrate
product efficacy and safety to the labeled crops. The EPA can require
submission of all efficacy and phytotoxicity data the company has acquired. The
registration dossier is subject to both scientific and administrative reviews
by EPA scientists and management before registration approval. The scientific
review involves thorough evaluation of submitted data and completion of risk
assessments for human dietary and ecotoxicological exposures. Upon completion
of this process, the registration package, including the proposed label, is
sent to the Office of General Council for legal review. The final step in the
registration process is administrative sign-off by the EPA director of the
Biopesticides and Pollution Prevention Division.
On June 20, 2000, the EPA granted conditional approval for full commercial
use of Serenade Biofungicide Wettable Powder. The conditional nature of this
approval does not impact our ability to market and sell Serenade, but the
approval for Serenade expires two years from the date of issue. For Serenade to
continue to be registered after June 20, 2002, we were required to submit to
the EPA by July 16, 2001 a two-year storage stability study and additional
studies on the effect of Serenade on selected non-target species. All of these
studies have been completed and submitted to the EPA, and indicate that
Serenade poses no foreseeable hazards to the non-target species. Upon review
and acceptance of these data, we believe that the EPA will convert the Serenade
registration from conditional to unconditional status. We are required to
submit one additional study to the EPA by May 2002. If we are unable to meet
the conditions specified by the EPA, however, the EPA could revoke our
registration or impose use restrictions that are not currently applicable to
Serenade.
As with any pesticide, our pest management products will continue to be
subject to review by the EPA and state regulatory agencies. The EPA has the
authority to revoke the registration or impose limitations on the use of any of
our pest management products if we do not comply with the regulatory
requirements, if unexpected problems occur with a product or the EPA receives
other newly discovered adverse information.
In addition to EPA approval, we are required to obtain regulatory approval
from the appropriate state regulatory authority in individual states and
foreign regulatory authorities before we can market or sell any pest management
product in those jurisdictions. Serenade is currently registered in 49 states
in the United States,
45
including California, the largest producer of fruits, nuts and vegetables in
the United States. We were also required to submit additional field data for
Serenade to the California EPA, which we submitted in July 2001. We have also
registered Serenade in Chile, Mexico and Puerto Rico. Our registration package
for Serenade in the European Union has been determined to be complete by the EU
Commission. However, until the registration is granted within the entire EU, we
must obtain provisional authorization approval in each country in order to
market and sell products in those countries. We have submitted applications for
Serenade registration in Argentina and New Zealand and expect approvals in
those countries.
Our manufacturing operations are also subject to federal, state, local and
foreign worker safety, air pollution, water pollution and solid and hazardous
waste regulatory programs and periodic inspection. We believe that our
facilities are in substantial compliance with all applicable environmental
regulatory requirements.
Competition
For pest management products, performance and value are critical competitive
factors. To compete against manufacturers of synthetic chemical pesticides and
genetically modified crops, we will need to demonstrate the advantages of our
products over these more established pest management products. Many large
agrichemical companies are developing and have introduced new chemical
pesticides and genetically modified products that they believe are safer and
more environmentally friendly than older synthetic chemical products.
The pest management market is very competitive and is dominated by
multinational chemical and life science companies, such as Aventis Pasteur,
BASF AG, Bayer AG, The Dow Chemical Co., E.I. du Pont de Nemours and Co.,
Monsanto Co., Sumitomo Chemical Co., Ltd. and Syngenta, AG. Universities,
research institutes and government agencies may also conduct research, seek
patent protection and, through collaborations, develop competitive pest
management products. Other companies, including biopesticide companies such as
Valent Biosciences Corp., EDEN Bioscience Corporation and Certis USA L.L.C.
(formerly Thermo Trilogy Corp.), may prove to be significant competitors in the
pest management market.
In many instances, agrichemical companies have substantially greater
financial, technical, development, distribution and sales and marketing
resources than we do. Moreover, these companies may have greater name
recognition than we do, and may offer discounts as a competitive tactic. We
cannot assure you that our competitors will not succeed in developing pest
management products that are more effective or less expensive than ours or that
would render our products obsolete or less competitive. Our success will depend
in large part on our ability to maintain a competitive position with our
technologies and products.
Employees
As of June 30, 2001, we had 65 full-time employees, of whom 16 hold Ph.D.
degrees. Approximately 32 employees are engaged in research and development,
ten in sales and marketing, nine in management, accounting/finance, regulatory
and administration in the United States. In addition, we have 14 employees
engaged in manufacturing at our facility in Mexico. None of our domestic
employees is represented by a labor union. We have entered into a collective
bargaining agreement with a labor union that represents two employees at our
manufacturing plant in Tlaxcala, Mexico. We consider our employee relations to
be good.
Facilities
We are headquartered in Davis, California, where we occupy approximately
13,000 square-feet of office, research and development, sales and marketing and
laboratory space under a lease that expires in July 2008. Our fermentation
pilot plant occupies approximately 3,000 square-feet of this facility. We also
own a 208,000 square-foot fermentation, manufacturing and extraction facility
on approximately 35 acres in Tlaxcala, Mexico.
Legal Proceedings
We may from time to time become a party to various legal proceedings arising
in the ordinary course of our business. We are not currently subject to any
legal proceeding.
46
MANAGEMENT
Executive Officers and Directors
The following table sets forth information regarding our executive officers
and directors and our key employees as of June 30, 2001.
Name Age Position
---- --- --------
Pamela G. Marrone, 44
Ph.D. ................. President, Chief Executive Officer and Chairman
Donald J. Glidewell..... 44 Vice President, Chief Financial Officer and Secretary
James Chambers.......... 35 Director of Sales and Marketing
Jennifer Ryder Fox, 51
Ph.D................... Vice President of Regulatory Affairs and Technical Development
G. Steven Burrill(2).... 56 Director
Jack Hunt(1)............ 56 Director
Frank F.C. Kung, 52
Ph.D.(1)............... Director
Walter Locher(2)........ 58 Director
Joe A. Mancini.......... 43 Director
George E. Myers(2)...... 43 Director
Ann Partlow(1).......... 57 Director
James A. 72
Schlindwein(2)......... Director
(1) Member of the Audit Committee.
(2) Member of the Compensation Committee.
Pamela G. Marrone, Ph.D. has served as our President and Chief Executive
Officer and as Chairman of our board of directors since our incorporation in
January 1995. From February 1990 to January 1995, Dr. Marrone served as
President of Novo Nordisk Entotech, Inc., a subsidiary of the biotechnology
company Novo Nordisk A/S. Dr. Marrone has also held various management
positions at Monsanto Company, a leading provider of agricultural solutions to
growers worldwide. She received her Ph.D. from North Carolina State University
and holds a B.S. degree with honors and distinction in Entomology from Cornell
University.
Donald J. Glidewell has served as our Vice President, Chief Financial
Officer and Secretary since May 2000. From November 1994 to May 2000, Mr.
Glidewell served as Chief Financial Officer of Bio-Trends International, a
biotechnology company. In February 1999, Mr. Glidewell filed a plan of
reorganization under Chapter 13 of the federal bankruptcy laws as a result of
three separate floods that severely damaged riverfront real estate owned by
him, each of which was declared a federal disaster. Mr. Glidewell is licensed
by the California Society of Certified Public Accountants and holds a B.S. in
Business Administration, Accounting from Arizona State University
James Chambers has served as our Director of Sales & Marketing since June
2001. From August 1995 to January 2001, Mr. Chambers held product development,
sales and marketing positions with Monsanto Company. Most recently, he was a
Product Manager for a biotechnology product. Prior to that, he was a Market
Manager for the Dairy Division. He has also managed a family farm. Mr. Chambers
has a B.S. in Economics & Marketing from Ohio State University.
Jennifer Ryder Fox, Ph.D. has served as our Vice President of Regulatory
Affairs and Technical Development since August 2001. From May 1998 to July
2001, she served as our Director of Regulatory Affairs. From November 1994 to
May 1998, Dr. Fox served as a Manager of Regulatory Affairs at the agricultural
products group of FMC Corporation, an agricultural chemical company. She
received her Ph.D. in Agronomy & Horticulture and her M.S. in Soil Science from
New Mexico State University and holds a B.S. in Soil Science from California
Polytechnic State University.
G. Steven Burrill has served as a director since July 1999. Mr. Burrill is
the Chief Executive Officer of Burrill & Company, a private merchant bank
focused on life science companies, which he founded in January 1996. Prior to
that, Mr. Burrill spent 27 years with Ernst & Young, including the last 17
years as a partner of
47
the firm. Mr. Burrill currently serves on the boards of directors of DepoMed,
Inc., Paradigm Genetics, Inc., Third Wave Technologies, Inc. and Transgene SA.
Mr. Burrill holds a B.B.A. degree from the University of Wisconsin, Madison.
Jack Hunt has served as a director since March 1998. Since May 1995, Mr.
Hunt has served as President and Chief Executive Officer of King Ranch, Inc., a
ranching and agricultural business company. Mr. Hunt currently serves as a
director of King Ranch, Inc. and St. Mary Land and Exploration Company. Mr.
Hunt also currently serves as a member of the Texas Water Development Board.
Mr. Hunt is a member of the Board of Trustees of Baylor College of Medicine. He
received his M.B.A. from Harvard University and holds a B.A. from Williams
College.
Frank F.C. Kung, Ph.D. has served as a director since March 1998. Since
January 1997, Dr. Kung has served as managing member of BioAsia Investments
LLC, a venture capital firm. From January 1984 to May 1996, Dr. Kung served as
Chairman and Chief Executive Officer of Genelabs Technologies, Inc., a
biopharmaceutical company. He received both his Ph.D. in Molecular Biology and
his M.B.A. from the University of California, Berkeley. He holds a B.S. in
Chemistry from the National TsingHwa University, Taiwan.
Walter Locher has served as a director since November 1999. Since October
1997, Mr. Locher has been a consultant with GSM, LLC, a consulting firm. From
December 1990 to September 1997, Mr. Locher served as the Chief Executive
Officer of Anderson Clayton Corp., a cotton and cottonseed processor, and
concurrently served as President of Volkart International, Inc., an
international cotton trading house. He currently serves as President of Volkart
America, Inc. He received his Diploma in Management from IMD, Lausanne and
holds a Diploma in Commerce from Commercial College, Winterthur, Switzerland.
Joe A. Mancini has served as a director since December 2000. Since June
1997, Mr. Mancini has served with CDC Group Plc, a global private equity firm.
He is currently director of technology-related investments at CDC Capital
Partners, a division of CDC Group Plc. From January 1991 to May 1997, Mr.
Mancini served as a director of Eurocontinental (Advisers) Limited, advisers to
Eurocontinental Ventures S.A., a European venture capital fund. He received his
M.B.A. from Schiller International University, London. He holds a B.Eng. in
Civil Engineering and a B.Sc. in Mathematics, both from the University of
Sydney, Australia.
George E. Myers has served as a director since May 1997. Since 1995, Mr.
Myers has served as President of Ojai Ranch and Investment Co., Inc., a venture
capital and agricultural business firm. He holds a B.S. in Agricultural
Economics and Business Management from the University of California, Davis.
Ann Partlow has served as a director since May 1997. Since April 1974, Ms.
Partlow has worked at Rockefeller & Company as a financial advisor and has
served as the investment manager of Rockefeller & Company's Odyssey Fund since
1977. She holds a B.A. in Economics from Connecticut College.
James A. Schlindwein has served as a director since June 1998. Mr.
Schlindwein has served as a consultant to Morgan Stanley since August 1994. Mr.
Schlindwein also serves on the board of directors of a number of private
companies, including Imperial Sugar Group, Chilay Corp., Eggs Innovation,
Alaska Seafood International and Emmpak Foods.
Key Research and Development Managers
Our key research and development managers lead our new product discovery and
development and have significant technical expertise in microbiology, natural
product chemistry, entomology, plant pathology, fermentation, product
formulation and field development. Our key research and development managers
are:
Denise C. Manker, Ph.D. Dr. Manker has served as our Research Manager since
January 1996 and leads our natural product chemistry, microbiology and
secondary testing teams. She also co-led the project team that developed
Serenade. From September 1990 to November 1995, Dr. Manker served as a staff
researcher at Novo
48
Nordisk Entotech, Inc., a subsidiary of the biotechnology company Novo Nordisk
A/S, where she established and managed the natural products chemistry
laboratory. Dr. Manker holds a Ph.D. from Scripps Institution of Oceanography
and served as a post-doctoral research associate at the University of
California, Davis.
Desmond R. Jimenez, Ph.D. Dr. Jimenez has served as our Staff Scientist
since November 1995 and leads our primary screening and entomology teams. From
June 1993 to November 1995, he was employed at Novo Nordisk Entotech, Inc.
where he led advanced testing of insecticidal natural products, high throughput
bioassays, and mode of action studies for Bt bioinsecticide. Dr. Jimenez holds
a Ph.D. in Food and Nutritional Sciences from the University of Arizona and
served as a post-doctoral research associate at the USDA-ARS Horticultural
Research Lab and the Carl Hayden Bee Research Center.
Jian-Er Lin, Ph.D. Dr. Lin has served as our Manager of Fermentation/Process
Development since July 2000 and is responsible for developing and scaling up
manufacturing processes for our natural products. From August 1994 to July
2000, he served as a group leader, applications and technical support for
Sybron Chemicals, Inc. Dr. Lin also held technical microbiology and engineering
positions at Celgene Corporation, the U.S. EPA Research Laboratory and the
Michigan Biotechnology Institute. Dr. Lin holds a Ph.D. in
Biotechnology/Biochemical Engineering from the University of Michigan.
Scientific Advisory Board
Our Scientific Advisory Board is comprised of individuals specializing in
the fields of natural product chemistry, microbiology, biochemistry and
fermentation who from time to time provide our management with specific
expertise in both research and product development. Non-employee members of our
Scientific Advisory Board have received stock options and some have received
cash compensation. Our Scientific Advisory Board currently consists of the
following individuals:
. William Fenical, Ph.D. Professor of Oceanography and Director, Center for
Marine Biotechnology and Biomedicine, Scripps Institute of Oceanography,
University of California, San Diego; Scientific Founder, Nereus
Pharmaceuticals, a marine microbial natural products pharmaceutical
company.
. Bruce Hammock, Ph.D. Professor, Department of Entomology and Cancer
Research Center, University of California, Davis; Program Director,
National Institute of Environment and Health Science Superfund Basic
Research Project; Member, National Academy of Sciences.
. Tadeusz Molinski, Ph.D. Professor, Department of Chemistry, University of
California, Davis.
. David Block, Ph.D. Associate Professor, Departments of Viticulture and
Enology and Chemical Engineering and Materials Science, University of
California, Davis.
Board of Directors
Our board of directors is currently comprised of nine directors. All of our
directors hold office until the next annual meeting of stockholders or until
their successors are duly elected and qualified. Our certificate of
incorporation to be effective upon completion of this offering provides that,
as of the first annual meeting of stockholders, our board of directors will be
divided into three classes, each with staggered three-year terms. As a result,
only one class of directors will be elected at each annual meeting of our
stockholders, with the other classes continuing for the remainder of their
respective three-year terms.
Messrs. Burrill and Mancini and Dr. Kung have been designated as Class I
directors, and their terms will expire at the 2002 annual meeting of
stockholders; Messrs. Hunt and Myers and Ms. Partlow have been designated as
Class II directors, and their terms will expire at the 2003 annual meeting of
stockholders; and Messrs. Locher and Schlindwein and Dr. Marrone have been
designated as Class III directors, and their terms will expire at the 2004
annual meeting of stockholders.
49
Board Committees
The audit committee of the board of directors was formed in May 1998 and
currently consists of Mr. Hunt, Dr. Kung and Ms. Partlow. The audit committee
reviews the results and scope of the annual audit and other services provided
by our independent auditors, reviews and evaluates our internal audit and
control functions and monitors transactions between us and our employees,
officers and directors.
The compensation committee of the board of directors was formed in May 1998
and currently consists of Messrs. Locher, Myers, Burrill and Schlindwein. The
compensation committee exercises the authority of our board of directors on all
compensation matters, including both cash and equity incentive compensation,
and administers our employee benefit plans.
Compensation Committee Interlocks and Insider Participation
None of our executive officers serves as a member of the board of directors
or compensation committee of any entity that has one or more executive officers
serving as a member of our board of directors or compensation committee.
Director Compensation
Our directors who are also employees receive no additional compensation for
their services as directors. Our non-employee directors do not receive a fee
for attendance in person at meetings of our board of directors or committees of
our board of directors, but they are reimbursed for travel expenses and other
out-of-pocket costs incurred in connection with their attendance at meetings.
In addition, our non-employee directors are eligible to receive options and be
issued shares of common stock directly under our 2001 non-employee director
stock option program. Upon the effective date of the registration statement
relating to this offering, each non-employee director will automatically be
granted an option to purchase 5,000 shares of our common stock with subsequent
annual options to purchase 5,000 shares of our common stock, both at an
exercise price per share equal to the fair market value of the common stock at
the date of grant. Our directors who are also employees are eligible to receive
options and be issued shares of common stock directly under our 2000 stock
incentive plan.
Executive Compensation
The following table sets forth information concerning the compensation that
we paid during the fiscal year ended December 31, 2000 for services rendered to
us in all capacities to our Chief Executive Officer and our most highly
compensated executive officers whose total salary, bonus and other compensation
exceeded $100,000 during that fiscal year. We refer to these persons as named
executive officers elsewhere in this prospectus. In accordance with the rules
of the Securities Exchange Commission, the compensation described in this table
does not include perquisites and other personal benefits received by the
executive officers named in the table below which do not exceed the lesser of
$50,000 or 10% of the total salary and bonus reported for these executive
officers.
Summary Compensation Table
Annual
Compensation Long-Term Compensation
-------------- -----------------------
Securities
Underlying All Other
Name and Principal Position Salary Bonus Options Compensation
--------------------------- -------- ----- ---------- ------------
Pamela G. Marrone, Ph.D. .............. $144,000 -- 115,250 --
President and Chief Executive Officer
Kurt Schwartau(1)...................... $108,000 -- 10,250 --
Former Vice President of Sales and
Marketing
(1) Mr. Schwartau ceased to be employed by us in March 2001.
50
Option Grants in Last Fiscal Year
The following table sets forth information concerning grants of stock
options to each of the named executive officers during the fiscal year ended
December 31, 2000. The percentage of total options set forth below is based on
an aggregate of 959,250 options granted to employees in 2000. Our board of
directors determined the fair market value of the options on the date of grant,
which is based on our financial results and prospects and our share price in
arms-length transactions. The exercise price may in some cases be paid by
delivery of other shares or by offset of the shares subject to options. The
deemed value on the date of grant has been adjusted solely for financial
accounting purposes. Potential realizable values are net of exercise price, but
before taxes associated with exercise. Amounts represent hypothetical gains
that could be achieved for the options if exercised at the end of the option
term. The assumed 5% and 10% rates of stock price appreciation are provided in
accordance with the rules of the Securities and Exchange Commission and do not
represent our estimate or projection of the future common stock price.
Potential
Realizable Value
at Assumed Annual
Rates of Stock
Price
Number of Percent of Appreciation for
Securities Total Options Option Term
Underlying Granted to Exercise Expiration -----------------
Name Options Employees Price Date 5% 10%
---- ---------- ------------- -------- ---------- -------- --------
Pamela G. Marrone,
Ph.D. ................. 12,250 1.3% $0.70 1/10/10 $ 5,393 $ 13,666
3,000 0.3% $0.70 4/15/10 $ 1,321 $ 3,347
100,000 10.4% $5.00 12/07/10 $314,447 $796,871
Kurt Schwartau(1)....... 10,250 1.1% $0.70 1/10/10 $ 4,512 $ 11,435
(1) Mr. Schwartau ceased to be employed by us in March 2001.
The following table sets forth information concerning exercisable and
unexercisable stock options held by each of the named executive officers at the
fiscal year ended December 31, 2000. The value realized upon exercise is based
on the estimated fair value of our common stock at the time of exercise less
the per share exercise price, multiplied by the number of shares acquired upon
exercise. The value of unexercised in-the-money options is based on the assumed
initial public offering price of $ per share less the per share exercise
price, multiplied by the number of shares underlying the options. An option is
in-the-money if the fair market value of the underlying shares exceeds the
exercise price of the option.
Aggregate Option Exercises in Last Fiscal Year and Year-End Option Values
Number of Securities Value of Unexercised
Underlying Options at In-the-Money Options at
Shares December 31, 2000 December 31, 2000
Acquired Value ------------------------- -------------------------
Name on Exercise Realized Exercisable Unexercisable Exercisable Unexercisable
---- ----------- -------- ----------- ------------- ----------- -------------
Pamela G. Marrone,
Ph.D. ................. 12,250 -- 3,000 100,000
Kurt Schwartau(1)....... -- -- 100,250 110,000
(1) Mr. Schwartau ceased to be employed by us in March 2001.
Employee Benefit Plans
1995 Stock Option Plan
Our 1995 stock option plan was approved by our board of directors and our
stockholders in May 1995. We have reserved a total of 2,500,000 shares of
common stock for issuance under our 1995 plan. As of June 30, 2001, options to
purchase 619,981 shares of common stock had been exercised, options to purchase
1,687,371 shares of common stock were outstanding and options to purchase
192,648 shares of common stock remained available for grant.
51
Awards under our 1995 plan may consist of incentive stock options, which are
stock options that qualify under Section 422 of the Internal Revenue Code, or
non-qualified stock options, which are stock options that do not qualify under
Section 422 of the Internal Revenue Code. Incentive stock options may be
granted to employees, including officers and employee directors of our company
or any parent, subsidiary or affiliate of our company. Non-qualified stock
options and restricted stock may be granted to employees, directors,
consultants and advisers of our company or any parent, subsidiary or affiliate
of our company.
A committee consisting of our board or appointed by our board administers
our 1995 plan. Subject to the terms of our 1995 plan, this committee has
authority to determine the terms and conditions of option grants.
The exercise price of options granted under our 1995 plan may not be less
than 100% of the fair market value of our common stock on the date of grant and
the term of an option may not exceed 10 years. If, however, incentive stock
options are granted to a person owning more than 10% of the total combined
voting power of all classes of stock of our company or any parent or subsidiary
of our company, the exercise price of such options may not be less than 110% of
the fair market value of our common stock on the date of grant and the term of
the option may not exceed 5 years.
In the case of incentive stock options, the aggregate fair market value of
stock for which the options are exercisable for the first time by an optionee
may not exceed $100,000. If the value of the stock exceeds $100,000, the
options for the amount in excess of $100,000 shall become nonqualified stock
options.
Options issued under our 1995 plan are not transferable, though the plan
administrator may approve the transfer of nonqualified stock options by non-
insider optionees to family members, trusts and charitable institutions.
Our 1995 plan provides that optionees who cease to be employed by our
company or any parent, subsidiary or affiliate of our company must exercise
their incentive stock options within 90 days, or twelve months in the case of
death or disability, and only to the extent they would have been exercisable
upon the date of termination.
In the event of one of the following, options under our 1995 plan will
become fully vested, unless the successor corporation assumes or substitutes
the options:
. a dissolution, liquidation or sale of all or substantially all of our
assets;
. a merger or consolidation in which we are not the surviving entity; or
. a corporate transaction wherein our stockholders give up all of their
equity interest in our company.
Our 1995 plan will terminate automatically in 2005 unless terminated earlier
by our board of directors. The board of directors has the authority to amend or
terminate our 1995 plan, subject to stockholder approval of some amendments.
However, no action may be taken which will affect any shares of common stock
previously issued and sold or any option previously granted under our 1995
plan, without the optionee's consent.
2000 Stock Incentive Plan
Our board of directors and our stockholders initially approved our 2000
stock incentive plan in December 2000. Our amended and restated 2000 stock
incentive plan was adopted by our board of directors in January 2001 and will
be submitted for approval by our stockholders prior to the completion of this
offering. We have reserved 2,000,000 shares of our common stock for issuance
under our 2000 stock incentive plan. As of June 30, 2001, options to purchase
737,645 shares of common stock were outstanding and options to purchase
1,262,355 shares of common stock remained available for grant under our 2000
stock incentive plan. The number of shares reserved for issuance under our 2000
stock incentive plan will increase annually on the first
52
business day of each calendar year beginning in January 2003 by an amount equal
to 500,000 shares. Our 2000 stock incentive plan provides for the grant of:
. incentive stock options to our employees, including officers and
employee directors;
. non-qualified stock options to our employees, directors and consultants;
and
. other types of awards.
We anticipate that all future option grants will be made solely under our
2000 stock incentive plan. The board of directors or a committee designated by
the board will administer our 2000 stock incentive plan, including selecting
the optionees, determining the number of shares to be subject to each option,
determining the exercise price of each option and determining the vesting and
exercise periods of each option.
The exercise price of all incentive stock options granted under our 2000
stock incentive plan must be at least equal to the fair market value of the
common stock on the date of grant. The exercise price of all nonstatutory stock
options granted under our 2000 stock incentive plan will be determined by the
board, but in no event may this price be less than 100% of the fair market
value of the common stock on the date of grant unless otherwise determined by
the board. If, however, incentive stock options are granted to one who owns
stock possessing more than 10% of the voting power of all our classes of stock,
the exercise price must equal at least 110% of the fair market value of the
common stock on the grant date and the maximum term of any of these options
must not exceed five years. The maximum term of an incentive stock option
granted to any participant who does not own stock possessing more than 10% of
the voting power of all our classes of stock must not exceed ten years. The
board will determine the term of all other awards granted under our 2000 stock
incentive plan.
Except as determined by the board, an option holder's initial grant will
vest at a rate no less than 25% per year, over four years from the date the
option is granted. Subsequent options will vest in the same manner.
In the event a participant in our 2000 stock incentive plan terminates
employment or is terminated by us for any reason, any options which have become
exercisable prior to the time of termination will remain exercisable for twelve
months from the date of termination if termination was caused by death or
disability, or three months from the date of termination if termination was
caused by reasons other than death or disability. In no event may an optionee
exercise the option after the expiration date of the term of an award in the
award agreement.
In the event of a corporate transaction or a change of control where the
acquiror assumes or replaces options granted under our 2000 stock incentive
plan, none of the options issued under this plan will be subject to accelerated
vesting under the plan. In the event of a corporate transaction or a change of
control where the acquiror does not assume or replace options granted under our
2000 stock incentive plan, all of these options become fully vested upon
consummation of the corporate transaction or change of control. Assumed or
replaced options will automatically become fully vested if the grantee is
terminated by the acquiror without cause or terminates employment for good
reason within twelve months of a corporate transaction or a change of control.
Under our 2000 stock incentive plan, a corporate transaction or a change in
control is defined as:
. acquisition of 50% or more of our stock by any individual or entity
including by tender offer or a reverse merger;
. change of a majority of the members on our board of directors;
. a sale, transfer or other disposition of all or substantially all of our
assets;
. a merger or consolidation in which we are not the surviving entity; or
. approval by our stockholders of a plan of complete liquidation.
53
Unless terminated sooner, our 2000 stock incentive plan will automatically
terminate in 2010. Our board of directors will have authority to amend or
terminate our 2000 stock incentive plan, provided that this type of action
would not impair the rights of any participant without the written consent of
that participant.
2001 Non-Employee Director Stock Option Program
Our 2001 non-employee director stock option program was adopted as part of
the 2000 stock incentive plan and will be subject to the terms and conditions
of the 2000 stock incentive plan. Our 2001 non-employee director stock option
program was approved by our board of directors in January 2001. The 2001 non-
employee director stock option program will become effective as of the
effective date of this prospectus, and no awards will be made under this
program until that time.
The purpose of the 2001 non-employee director stock option program will be
to enhance our ability to attract and retain the best available non-employee
directors, to provide them additional incentives and, therefore, to promote the
success of our business.
The 2001 non-employee director stock option program will establish an
automatic option grant program for the grant of awards to non-employee
directors. Under this program, each then-existing non-employee director upon
the effective date of this prospectus will automatically be granted an option
to acquire 5,000 shares of our common stock at an exercise price per share
equal to the fair market value of our common stock at the date of grant. Each
non-employee director first elected to our board of directors following the
closing of this offering will automatically be granted an option to acquire
10,000 shares of our common stock at an exercise price per share equal to the
fair market value of our common stock at the date of grant. Upon the date of
each annual stockholders' meeting, each non-employee director who continues as
a member of our board of directors following the stockholders' meeting, and who
has served as a director for at least eleven months, will receive an automatic
grant of options to acquire 5,000 shares of our common stock at an exercise
price equal to the fair market value of our common stock at the date of grant.
These options will vest on a quarterly basis and become fully exercisable on
the first anniversary of the grant date.
The term of each automatic option grant and the extent to which it will be
transferable will be provided in the agreement evidencing the option. The
consideration for the option may consist of cash, shares of our common stock,
the assignment of part of the proceeds from the sale of shares acquired upon
exercise of the option or any combination of these forms of consideration.
The 2001 non-employee director stock option program will be administered by
the board or a committee designated by the board made up of two or more non-
employee directors so that such awards would be exempt from Section 16(b) of
the Exchange Act. The program administrator shall determine the terms and
conditions of awards, and construe and interpret the terms of the program and
awards granted under the program. Non-employee directors may also be granted
additional incentives, subject to the discretion of the board or the committee.
Unless terminated sooner, the 2001 non-employee director stock option
program will terminate automatically in 2010 when the 2000 stock incentive plan
terminates. Our board of directors will have the authority to amend, suspend or
terminate the 2001 non-employee director stock option program provided that no
such action may affect awards to non-employee directors previously granted
under the program unless agreed to by the affected non-employee directors.
2001 Employee Stock Purchase Plan
Our 2001 employee stock purchase plan was adopted by our board of directors
in January 2001 and will be submitted for approval by our stockholders prior to
the completion of this offering. Our 2001 employee stock purchase plan is
intended to qualify as an "Employee Stock Purchase Plan" under Section 423 of
the Internal Revenue Code in order to provide our employees with an opportunity
to purchase common stock
54
through payroll deductions. An aggregate of 350,000 shares of common stock will
be reserved for issuance and will be available for purchase under our 2001
employee stock purchase plan, pending adjustment for a stock split or any
future stock dividend or other similar change in our common stock or our
capital structure. Our 2001 employee stock purchase plan will provide for
annual increases in the number of shares of common stock subject to the plan
equal to the lesser of:
. 200,000 shares;
. the number of shares equal to 0.75% of the total number of shares
outstanding; or
. a lesser number of shares as determined by the compensation committee.
All of our employees who are regularly employed for more than five months in
any calendar year and work more than 20 hours per week will be eligible to
participate in our 2001 employee stock purchase plan and will be automatically
enrolled in the initial offer period. Employees hired after the consummation of
our initial public offering will be eligible to participate in our 2001
employee stock purchase plan, subject to a three day waiting period after
hiring. Non-employee directors, consultants and employees subject to the rules
or laws of a foreign jurisdiction that prohibit or make impractical their
participation in an employee stock purchase plan will not be eligible to
participate in our 2001 employee stock purchase plan.
Our 2001 employee stock purchase plan will designate offer periods, purchase
periods and exercise dates. Offer periods will generally be overlapping periods
of 24 months. The initial offer period will begin on the effective date of our
2001 employee stock purchase plan, which is the effective date of the
registration statement relating to this offering, and ends on December 31,
2003. Additional offer periods will commence each January 1 and July 1.
Purchase periods will generally be six month periods, with the initial purchase
period commencing on the effective date of our 2001 employee stock purchase
plan and ending on June 30, 2002. Thereafter, purchase periods will commence
each January 1 and July 1. Exercise dates are the last day of each purchase
period. In the event we merge with or into another corporation, sell all or
substantially all of our assets or enter into other transactions in which all
of our stockholders before the transaction own less than 50% of the total
combined voting power of our outstanding securities following the transaction,
the administrator of our 2001 employee stock purchase plan may elect to shorten
the offer period then in progress.
On the first day of each offer period, a participating employee will be
granted a purchase right. A purchase right is a form of option to be
automatically exercised on the forthcoming exercise dates within the offer
period during which authorized deductions are to be made from the pay of
participants and credited to their accounts under our 2001 employee stock
purchase plan. When the purchase right is exercised, the participant's withheld
salary is used to purchase shares of common stock. The price per share at which
shares of common stock are to be purchased under our 2001 employee stock
purchase plan during any purchase period is the lesser of:
. 85% of the fair market value of the common stock on the date of the grant
of the option, which is the commencement of the offer period; or
. 85% of the fair market value of the common stock on the exercise date,
which is the last day of a purchase period.
The participant's purchase right is exercised in this manner on each
exercise date arising in the offer period unless, on the first day of any
purchase period, the fair market value of the common stock is lower than the
fair market value of the common stock on the first day of the offer period. If
so, the participant's participation in the original offer period is terminated
and the participant is automatically enrolled in the new offer period effective
the same date.
Payroll deductions may range from 1% to 10% in whole percentage increments
of a participant's regular base pay, exclusive of bonuses, overtime, shift-
premiums, commissions, reimbursements or other expense allowances. Participants
in the first purchase period must purchase shares through a direct cash
payment. Once the shares reserved for issuance under our 2001 employee stock
purchase plan have been registered on Form S-8
55
under the Securities Act, participants in the first purchase period may elect
to purchase shares through payroll deductions. After the first purchase period,
participants may not make direct cash payments to their accounts. The maximum
number of shares of common stock that any employee may purchase under our 2001
employee stock purchase plan during a purchase period is 1,750 shares. The
Internal Revenue Code imposes additional limitations on the amount of common
stock that may be purchased during any calendar year.
Our 2001 employee stock purchase plan will be administered by our board of
directors or a committee designated by our board, which will have the authority
to terminate or amend our 2001 employee stock purchase plan, subject to
specified restrictions, and otherwise to administer our 2001 employee stock
purchase plan and to resolve all questions relating to the administration of
our 2001 employee stock purchase plan.
401(k) Plan
In 1996, we implemented a 401(k) plan covering some of our employees. Under
the 401(k) plan, eligible employees may elect to reduce their current
compensation up to the prescribed annual limit, which was $10,500 in 2000, and
contribute these amounts to the 401(k) plan. We may make contributions to the
401(k) plan on behalf of eligible employees. Employees become fully vested in
these contributions immediately, subject to limitations on access to the
contributions during the duration of employment. The 401(k) plan is intended to
qualify under Section 401 of the Internal Revenue Code so that contributions by
employees or by us to the 401(k) plan, and income earned on the 401(k) plan
contributions, are not taxable to employees until withdrawn from the 401(k)
plan and so that contributions by us, if any, will be deductible by us when
made. The trustee under the 401(k) plan, at the direction of each participant,
invests the 401(k) plan employee salary deferrals in selected investment
options. We made no contributions to the 401(k) plan in 1996, 1997, 1998, 1999
or 2000. We currently do not expect to make contributions to the 401(k) plan in
2001.
Limitations on Liability and Indemnification
Our certificate of incorporation and bylaws provide that we will indemnify
all of our directors and officers to the fullest extent permitted by Delaware
law. Our certificate of incorporation and bylaws also authorize us to indemnify
our employees and other agents, at our option, to the fullest extent permitted
by Delaware law. We intend to enter into agreements to indemnify our directors
and officers, in addition to indemnification provided for in our charter
documents. These agreements, among other things, will provide for the
indemnification of our directors and officers for expenses, including
attorneys' fees, judgments, fines and settlement amounts incurred by any person
in any action or proceeding, including any action by or in the right of our
company, arising out of that person's services as a director or officer of our
company or any other company or enterprise to which that person provides
services at our request to the fullest extent permitted by applicable law. We
believe that these provisions and agreements will assist us in attracting and
retaining qualified persons to serve as directors and officers.
Delaware law permits a corporation to provide in its certificate of
incorporation that a director of the corporation shall not be personally liable
to the corporation or its stockholders for monetary damages for breach of
fiduciary duty as a director, except for liability for any breach of the
director's duty of loyalty to the corporation or its stockholders, for acts or
omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, for liability arising under Section 174 of the
Delaware General Corporation Law or for any transaction from which the director
derived an improper personal benefit. Our certificate of incorporation provides
for the elimination of personal liability of a director for breach of fiduciary
duty, as permitted by Delaware law.
Insofar as indemnification for liabilities arising under the Securities Act
of 1933, as amended, may be permitted to directors, officers and controlling
persons of our company in accordance with the provisions contained in our
charter documents, Delaware law or otherwise, we have been advised that in the
opinion of the Securities and Exchange Commission this indemnification is
against public policy as expressed in the Securities Act and is, therefore,
unenforceable. If a claim for indemnification against these liabilities, other
than
56
the payment by us of expenses incurred or paid by a director, officer or
controlling person of our company in the successful defense of any action, suit
or proceeding, is asserted by a director, officer or controlling person, we
will, unless, in the opinion of our counsel, the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by us is against public policy as
expressed in the Securities Act and we will follow the court's determination.
We intend to purchase and maintain insurance on behalf of our officers and
directors, insuring them against liabilities that they may incur in such
capacities or arising out of this status.
There is no pending litigation or proceeding involving any of our directors
or officers as to which indemnification is being sought, nor are we aware of
any pending or threatened litigation that may result in claims for
indemnification by any director or officer.
57
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Since January 1998, we issued the following securities to various investors
in private placement transactions:
. 3,523,535 shares of our Series C preferred stock at a purchase price of
$1.70 per share between March 1998 and April 1998;
. 3,015,306 shares of our Series D preferred stock, as adjusted for our
July 1999 stock split, at a purchase price of $2.35 per share between
April 1999 and September 1999;
. 2,251,919 shares of our Series E preferred stock at a purchase price of
$3.20 per share in April 2000; and
. 2,976,333 shares of our Series F preferred stock at a weighted-average
purchase price of $5.03 per share in December 2000.
Each share of preferred stock will convert automatically into one share of
common stock upon the closing of this offering. The investors in these
financings included the following directors, executive officers and holders of
more than 5% of our outstanding stock and their affiliates:
Preferred Stock
---------------------------------
Series Series Series
Purchasers Series C D E F
---------- --------- ------- ------- -------
Odyssey Fund Rockefeller & Co., Inc.(1)..... 441,177 425,531 156,250 100,000
BioAsia Investments, LLC and its
affiliates(2).............................. 1,176,471 212,766 62,500 50,000
Milagro de Ladera, L.P.(3).................. 352,942 319,147 78,360 100,000
Burrill Agbio Capital Fund L.P.(4).......... -- 851,064 -- 200,000
Swiss Reinsurance Company................... -- -- 781,250 200,000
Volkart Holdings Ltd. and its
affiliates(5).............................. 147,058 106,382 78,318 400,000
King Ranch Investments, L.P.(6)............. 588,236 106,382 78,425 --
J.S.S. Management Co., Ltd. and its
affiliates(7).............................. 117,647 106,383 62,688 100,000
SAM Sustainability Private Equity, L.P. and
its affiliate(8)........................... -- -- -- 800,000
CDC Financial Services (Mauritius)
Limited(9)................................. -- -- -- 550,000
(1) Ann Partlow serves on our board of directors and is the investment manager
of Odyssey Fund Rockefeller & Co., Inc.
(2) Includes 784,118 shares of Series C preferred stock held of record by
Biotechnology Development Fund III, L.P., 392,353 shares of Series C
preferred stock held of record by Biotechnology Development Fund, L.P.,
141,486 shares of Series D preferred stock held of record by Biotechnology
Development Fund III, L.P., 71,280 shares of Series D preferred stock held
of record by Biotechnology Development Fund, L.P., 62,500 shares of Series
E preferred stock held of record by Biotechnology Development Fund, L.P.,
and 50,000 shares of Series F preferred stock held of record by
Biotechnology Development Fund, L.P. Dr. Kung serves on our board of
directors and is the managing member of these entities.
(3) George E. Myers serves on our board of directors and is a limited partner
of Milagro de Ladera, L.P.
(4) G. Steven Burrill serves on our board of directors and is the chief
executive officer of Burrill & Company, which is the general partner of
Burrill Agbio Capital Fund, L.P.
(5) Includes 147,058 shares of Series C preferred stock, 106,382 shares of
Series D preferred stock and 78,318 shares of Series E preferred stock held
of record by Volkart Holdings Ltd., 300,000 shares of Series F preferred
stock held of record by Volkart Foundation and 100,000 shares of Series F
preferred stock held of record by Andreas Reinhart, who is the president of
the Volkart entities.
58
(6) Jack Hunt serves on our board of directors and is the president and chief
executive officer of King Ranch, Inc. Running W, Ltd. is the general
partner of King Ranch Investments, L.P. and is a wholly-owned subsidiary of
King Ranch, Inc.
(7) Includes 40,000 shares of Series F preferred stock, 62,688 shares of Series
E preferred stock and 85,106 shares of D preferred stock held of record by
J.S.S. Management Co., Ltd., 20,000 shares of Series F preferred stock and
21,277 shares of Series D preferred stock held of record by Suzanne S.
Schlindwein and 40,000 shares of Series F preferred stock held of record by
James A. Schlindwein. Mr. Schlindwein serves on our board of directors and
is a trustee of J.S.S. Management Co., Ltd. Suzanne Schlindwein is the wife
of James Schlindwein.
(8) Includes 400,000 shares of Series F preferred stock held of record by SAM
Sustainability Private Equity, L.P. and 400,000 shares of Series F
preferred stock held of record by Sustainable Performance Group N.V. Walter
Locher serves on our board of directors and is a principal of SAM Equity
Partners Ltd., which is the general partner of SAM Sustainability Private
Equity, L.P. and manages the Sustainable Performance Group N.V.
(9) Joe A. Mancini serves on our board of directors and is director of
technology-related investments at CDC Capital Partners, a division of CDC
Group Plc. CDC Group Plc is the parent company of CDC Financial Services
(Mauritius) Limited.
We have entered into agreements with holders of our preferred stock whereby
we granted them registration rights with respect to their shares of common
stock, including common stock issuable upon conversion of their preferred
stock. See "Description of Capital Stock--Registration Rights."
We intend to enter into indemnification agreements with each of our
directors and officers. These indemnification agreements will require us to
indemnify these individuals to the fullest extent permitted by Delaware law.
We believe that all of the transactions set forth above were made on terms
no less favorable to us than could have been obtained from unaffiliated third
parties. We intend that all future transactions, including loans, between us
and our officers, directors, principal stockholders and their affiliates will
be approved by a majority of our board of directors, including a majority of
the independent and disinterested outside directors on our board of directors,
and will be on terms no less favorable to us than could be obtained from
unaffiliated third parties.
59
PRINCIPAL STOCKHOLDERS
The following table sets forth information with respect to the beneficial
ownership of our common stock as of June 30, 2001 by:
. each person or entity known by us to own beneficially more than five
percent of our common stock;
. each of our directors and named executive officers; and
. all of our directors and named executive officers as a group.
This table calculates applicable percentage ownership based on 18,591,832
shares of our common stock issued and outstanding as of June 30, 2001, assuming
the conversion of all outstanding shares of preferred stock into common stock,
which will occur automatically upon the effectiveness of this offering. It also
calculates applicable percentage ownership based on shares of common
stock outstanding immediately following the completion of this offering.
Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission and generally includes voting or investment
power with respect to securities. Shares issuable upon the exercise of options
that are currently exercisable or become exercisable within 60 days of June 30,
2001 are considered outstanding for the purpose of calculating the percentage
of outstanding shares of our common stock held by the individual, but not for
the purpose of calculating the percentage of outstanding shares of our common
stock held by any other individual. Except as indicated in the footnotes to
this table and as affected by applicable community property laws, all persons
listed below have sole voting and investment power for all shares shown as
beneficially owned by them.
Except as otherwise noted, the address of each person or entity in the
following table is c/o AgraQuest, Inc., 1530 Drew Avenue, Davis, California
95616.
Percentage of
Shares
Beneficially
Number of Owned
Shares -----------------
Beneficially Before After
Beneficial Owner Owned Offering Offering
---------------- ------------ -------- --------
5% Stockholders
Odyssey Fund Rockefeller & Co., Inc.(1)........ 1,837,244 9.9%
BioAsia Investments, LLC and its
affiliates(2)................................. 1,501,737 8.1%
Milagro de Ladera, L.P.(3)..................... 1,326,640 7.1%
Burrill Agbio Capital Fund L.P.(4)............. 1,051,064 5.7%
Swiss Reinsurance Company(5)................... 981,250 5.3%
Volkart Holdings Ltd. and its affiliates(6).... 969,853 5.2%
Named Executive Officers and Directors
Pamela G. Marrone, Ph.D.(7).................... 1,357,450 7.3%
Kurt Schwartau................................. 110,250 *
G. Steven Burrill(8)........................... 1,063,064 5.7%
Jack Hunt(9)................................... 799,045 4.3%
Frank F.C. Kung, Ph.D.(10)..................... 1,527,737 8.2%
Walter Locher(11).............................. 1,614,000 8.7%
Joe A. Mancini(12)............................. -- *
George E. Myers(13)............................ 1,369,140 7.4%
Ann Partlow(14)................................ 1,879,744 10.1%
James A. Schlindwein(15)....................... 463,956 2.5%
All named executive officers and directors as a
group (10 persons)............................ 10,184,386 54.5%
* Less than 1%.
(1) The business address of Odyssey Fund Rockefeller & Co., Inc. is 30
Rockefeller Plaza, Room 5425, New York, NY 10112.
60
(2) Includes 925,604 shares held of record by Biotechnology Development Fund
III, L.P. and 576,133 shares held of record by Biotechnology Development
Fund, L.P. The business address of BioAsia Investments, LLC is 575 High
Street, Suite 201, Palo Alto, CA 94301.
(3) The business address of Milagro de Ladera, L.P. is 1114 State Street,
Suite 232, Santa Barbara, CA 93101.
(4) The business address of Burrill Agbio Capital Fund L.P. is 120 Montgomery
Street, #1370, San Francisco, CA 94104.
(5) The business address of Swiss Reinsurance Company is Mythenquai 50/60,
P.O. Box 8022, Zurich, Switzerland.
(6) Includes 225,376 shares held of record by Volkart Holdings Ltd., 300,000
shares held of record by Volkart Foundation and 100,000 shares held of
record by Andreas Reinhart, who is the president of the Volkart entities.
The business address of Volkart Holdings Ltd. is Turnerstr. 1, 8401
Winterthur, Switzerland.
(7) Includes 3,000 shares issuable upon exercise of options within 60 days of
June 30, 2001.
(8) Includes 12,000 shares issuable upon exercise of options within 60 days of
June 30, 2001 and 1,051,064 shares held of record by Burrill Agbio Capital
Fund L.P. Mr. Burrill is the chief executive officer of Burrill & Company,
which is the general partner of Burrill Agbio Capital Fund L.P. Mr.
Burrill disclaims beneficial ownership of these shares except to the
extent of his pecuniary interest therein.
(9) Includes 26,000 shares issuable upon exercise of options within 60 days of
June 30, 2001 and 773,045 shares held of record by King Ranch Investments,
L.P. Running W, Ltd. is the general partner of King Ranch Investments,
L.P. and a wholly-owned subsidiary of King Ranch, Inc., of which Mr. Hunt
is the president and chief executive officer. Mr. Hunt disclaims
beneficial ownership of these shares except to the extent of his pecuniary
interest therein.
(10) Includes 12,000 shares held of record by Dr. Kung, 12,000 shares issuable
upon exercise of options within 60 days of June 30, 2001 and 1,501,737
shares held of record by BioAsia Investments, LLC and its affiliates, of
which Dr. Kung is the managing member. Dr. Kung disclaims beneficial
ownership of these shares except to the extent of his pecuniary interest
therein.
(11) Includes 8,000 shares held of record by Mr. Locher, 6,000 shares issuable
upon exercise of options within 60 days of June 30, 2001, 400,000 shares
held of record by SAM Sustainability Private Equity, L.P. and 400,000
shares held of record by Sustainable Performance Group N.V. Mr. Locher is
a principal of SAM Equity Partners Ltd., which is the general partner of
SAM Sustainability Private Equity, L.P. and manages the Sustainable
Performance Group N.V. Mr. Locher disclaims beneficial ownership of these
shares except to the extent of his pecuniary interest therein.
(12) Excludes 550,000 shares held of record by CDC Financial Services
(Mauritius) Limited. Mr. Mancini is director of technology-related
investments at CDC Capital Partners, a division of CDC Group Plc.
CDC Group Plc is the parent company of CDC Financial Services (Mauritius)
Limited.
(13) Includes 35,000 shares held of record by Mr. Myers, 7,500 shares issuable
upon exercise of options within 60 days of June 30, 2001 and 1,326,640
shares held of record by Milagro de Ladera L.P., of which Mr. Myers is a
limited partner. Mr. Myers disclaims beneficial ownership of these shares
except to the extent of his pecuniary interest therein.
(14) Includes 42,500 shares issuable upon exercise of options within 60 days of
June 30, 2001 and 1,837,244 shares held of record by Odyssey Fund
Rockefeller & Co., Inc., of which Ms. Partlow is the investment manager.
Ms. Partlow disclaims beneficial ownership of these shares except to the
extent of her pecuniary interest therein.
(15) Includes 16,000 shares held of record by Mr. Schlindwein, 6,000 shares
issuable upon exercise of options within 60 days of June 30, 2001, 400,679
shares held of record by J.S.S. Management Co., Ltd., of which Mr.
Schlindwein is a trustee, and 41,277 shares held of record by Suzanne
Schlindwein, who is the wife of Mr. Schlindwein. Mr. Schlindwein disclaims
beneficial ownership of these shares except to the extent of his pecuniary
interest therein.
61
DESCRIPTION OF CAPITAL STOCK
The following information describes our common stock and preferred stock, as
well as options to purchase our common stock, and provisions of our certificate
of incorporation and our bylaws. This description is only a summary. You should
also refer to our certificate of incorporation and bylaws that have been filed
with the Securities and Exchange Commission as exhibits to our registration
statement, of which this prospectus forms a part.
Upon the completion of this offering, we will be authorized to issue up to
66,000,000 shares of capital stock, $0.001 par value per share. Of these
authorized shares, 60,000,000 shares will be designated as common stock and
6,000,000 shares will be designated as preferred stock.
Common Stock
As of June 30, 2001, there were 3,688,239 shares of common stock outstanding
that were held of record by approximately 72 stockholders. After giving effect
to the sale of the common stock we are offering, there will be shares of
common stock outstanding, assuming no exercise of the underwriters' over-
allotment option and conversion of all outstanding shares of preferred stock
into common stock.
The holders of our common stock are entitled to one vote for each share held
of record upon such matters and in such manner as may be provided by law.
Subject to preferences applicable to any outstanding shares of preferred stock,
the holders of common stock are entitled to receive dividends ratably, if any,
as may be declared by our board of directors out of funds legally available for
dividend payments. In the event we liquidate, dissolve or wind up, the holders
of common stock are entitled to share ratably in all assets remaining after
payment of liabilities and liquidation preferences of any outstanding shares of
the preferred stock. Holders of common stock have no preemptive rights or
rights to convert their common stock into any other securities. There are no
redemption or sinking fund provisions applicable to the common stock. All
outstanding shares of common stock are validly issued, fully paid and
nonassessable, and the shares of common stock to be issued in this offering
will be validly issued, fully paid and nonassessable.
Preferred Stock
As of June 30, 2001, there were 14,903,593 shares of preferred stock
outstanding that were held of record by approximately 55 stockholders. In
connection with the closing of this offering, all outstanding shares of our
preferred stock will automatically be converted into common stock on a one-for-
one basis. Upon the closing of this offering, we will be authorized to issue
6,000,000 shares of preferred stock that will not be designated as a particular
class. Our board of directors will have authority to issue the undesignated
preferred stock in one or more series and to determine the powers, preferences
and rights and the qualifications, limitations or restrictions granted to or
imposed upon any wholly unissued series of undesignated preferred stock and to
fix the number of shares constituting any series and the designation of the
series, without any further vote or action by our stockholders. The issuance of
preferred stock, while providing desirable flexibility in connection with
possible acquisitions and other corporate purposes, could have the effect of
making it more difficult for a third party to acquire, or of discouraging a
third party from attempting to acquire, a majority of our outstanding voting
stock. We have no present plans to issue any shares of preferred stock.
Warrants
In December 1998, in connection with a financing arrangement, we issued a
warrant to purchase (a) 31,200 shares of our Series C preferred stock to
MMC/GATX Partnership No. 1 and (b) 7,800 shares of our Series C preferred stock
to Silicon Valley Bank, each with an exercise price of $1.70 per share. These
warrants are exercisable at any time prior to the earlier of December 23, 2008
or five years after the closing of this offering. Upon the closing of this
offering, these warrants will be exercisable for an aggregate of 39,000 shares
of our common stock at an exercise price of $1.70 per share.
62
Registration Rights
After the closing of this offering, the holders of approximately 16,977,557
shares of our common stock will be entitled to registration rights with respect
to their shares. Beginning three months after the closing of this offering, the
holders of approximately 30% of these securities may require us to register all
or part of their shares. In addition, these holders may require us to include
their shares in future registration statements that we file and may require us
to register their shares on Form S-3. Upon registration, these shares will be
freely tradable in the public market without restriction.
All expenses in effecting these registrations, with the exception of
underwriting discounts and selling commissions, will be borne by us. These
registration rights are subject to some conditions and limitations, among them
the right of the underwriters of an offering to limit the number of shares
included in the registration. We have agreed to indemnify the holders of these
registration rights, and each selling holder has agreed to indemnify us,
against liabilities under the Securities Act, the Securities Exchange Act or
other applicable federal or state law.
Anti-Takeover Effects of Provisions of our Charter Documents and Bylaws and
Delaware Law
Provisions of Delaware law and our certificate of incorporation and bylaws
could make our acquisition by means of a tender offer, a proxy contest, or
otherwise, and the removal of incumbent officers and directors more difficult.
These provisions are expected to discourage types of coercive takeover
practices and inadequate takeover bids and to encourage persons seeking to
acquire control to first negotiate with us. We believe that the benefits of
increased protection of our potential ability to negotiate with the proponent
of an unfriendly or unsolicited proposal to acquire or restructure us outweighs
the disadvantages of discouraging proposals, including proposals that are
priced above the then current market value of our common stock, because, among
other things, negotiation of these proposals could result in an improvement of
their terms.
Delaware Law
We are subject to Section 203 of the Delaware General Corporation Law. Under
this provision, we may not engage in any business combination with any
interested stockholder for a period of three years following the date that
stockholder became an interested stockholder, unless:
. prior to that date the board of directors approved either the business
combination or the transaction that resulted in the stockholder becoming
an interested stockholder;
. upon completion of the transaction that resulted in the stockholder
becoming an interested stockholder, the interested stockholder owned at
least 85% of the voting stock outstanding at the time the transaction
began; or
. on or following that date, the business combination is approved by the
board of directors and authorized at an annual or special meeting of
stockholders by the affirmative vote of at least 66 2/3% of the
outstanding voting stock that is not owned by the interested
stockholder.
Section 203 defines "business combination" to include:
. any merger or consolidation involving the corporation and the interested
stockholder;
. any sale, transfer, pledge or other disposition of assets with an
aggregate market value equal to 10% or more of the aggregate market
value of all assets of the corporation or the aggregate market value of
all outstanding stock of the corporation involving the interested
stockholder;
. subject to some exceptions, any transaction that results in the issuance
or transfer by the corporation of any stock of the corporation to the
interested stockholder;
. any transaction involving the corporation that has the effect of
increasing the proportionate share of the stock of any class or series
of the corporation beneficially owned by the interested stockholder; or
. the receipt by the interested stockholder of the benefit of any loans,
advances, guarantees, pledges or other financial benefits provided by or
through the corporation.
63
In general, Section 203 defines an interested stockholder as any entity or
person beneficially owning 15% or more of the outstanding voting stock of the
corporation and any entity or person affiliated with or controlling or
controlled by the entity or person.
Certificate of Incorporation and Bylaws
Our certificate of incorporation and bylaws will contain provisions that
could have the effect of discouraging potential acquisition proposals or tender
offers or delaying or preventing a change in control of our company. In
particular, our certificate of incorporation and bylaws, as applicable, among
other things, will:
. provide that our board of directors will be divided into three classes
of directors, as nearly equal in number as is reasonably possible,
serving staggered terms so that directors' initial terms will expire at
the first, second and third succeeding annual meeting of the
stockholders following our initial public offering, respectively. At
each such succeeding annual meeting, directors elected to succeed those
directors whose terms are expiring at such meeting shall be elected for
a three-year term of office. A vote of at least 80% of our capital stock
would be required to amend this provision;
. provide that special meetings of the stockholders may be called only by
our president, our secretary or at the direction of the board. Advance
written notice of a stockholder proposal or director nomination that the
stockholder desires to present at a meeting of stockholders is required
and generally must be received by the secretary not less than 45 days
nor more than 75 days prior to the meeting;
. not include a provision for cumulative voting in the election of
directors. Under cumulative voting, a minority stockholder holding a
sufficient number of shares may be able to ensure the election of one or
more directors. The absence of cumulative voting may have the effect of
limiting the ability of minority stockholders to effect changes in the
board and, as a result, may have the effect of deterring a hostile
takeover or delaying or preventing changes in control or management of
our company;
. provide that vacancies on our board may be filled by a majority of
directors in office, although less than a quorum, and not by the
stockholders; and
. allow us to issue up to 6,000,000 shares of undesignated preferred stock
with rights senior to those of the common stock and that otherwise could
adversely affect the rights and powers, including voting rights, of the
holders of common stock. In some circumstances, this issuance could have
the effect of decreasing the market price of the common stock as well as
having the anti-takeover effect discussed above.
These provisions are intended to enhance the likelihood of continuity and
stability in the composition of our board and in the policies formulated by
them and to discourage certain types of transactions that may involve an actual
or threatened change in control of us. These provisions are designed to reduce
our vulnerability to an unsolicited acquisition proposal and to discourage
certain tactics that may be used in proxy fights. However, these provisions
could have the effect of discouraging others from making tender offers for our
shares that could result from actual or rumored takeover attempts. These
provisions also may have the effect of preventing changes in our management.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is American Stock
Transfer & Trust Company. Its address is 59 Maiden Lane, Plaza Level, New York,
NY 10038, and its telephone number is (212) 936-5100.
Quotation on the Nasdaq National Market
We have applied to list our common stock on the Nasdaq National Market under
the symbol "AGRQ."
64
SHARES ELIGIBLE FOR FUTURE SALE
Prior to this offering, there has been no public offering for our common
stock. Future sales of substantial amounts of our common stock in the public
market could adversely affect prevailing market prices. Only a limited number
of shares will be available for sale shortly after this offering because of
contractual and legal restrictions on resale. Accordingly, sales of substantial
amounts of our common stock in the public market after these restrictions lapse
could adversely affect prevailing market prices and our ability to raise equity
capital in the future.
Upon completion of this offering, we will have shares of common stock
outstanding, assuming no exercise of options or warrants after June 30, 2001
and assuming the conversion of all shares of preferred stock outstanding into
common stock, based on shares outstanding as of June 30, 2001. Of these shares,
the shares of common stock sold in this offering, plus any shares issued
upon exercise of the underwriters' over-allotment option, will be freely
transferable without restriction or registration under the Securities Act,
except for shares purchased by any of our existing "affiliates," which
generally include officers, directors or 10% stockholders, as that term is
defined in Rule 144 under the Securities Act. The remaining shares of
common stock outstanding upon completion of this offering are "restricted
securities" within the meaning of Rule 144 under the Securities Act. These
shares may be sold in the public market only if registered, or if they qualify
for an exemption from registration under Rule 144, Rule 144(k) or 701
promulgated under the Securities Act, each of which is summarized below.
Including our directors and executive officers, holders of a total of
approximately shares of common stock, including shares issuable upon
automatic conversion of the outstanding preferred stock, have entered into
lock-up agreements generally providing that they will not, without the prior
written consent of Merrill Lynch, Pierce, Fenner & Smith Incorporated, directly
or indirectly, offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant for the sale of, or otherwise dispose of or transfer
any shares of common stock or any securities convertible into or exercisable or
exchangeable for common stock, subject to some exceptions, for a period of 180
days after the date of this prospectus. We have entered into a similar
agreement with Merrill Lynch. As a result of these contractual restrictions,
notwithstanding possible earlier eligibility for sale under the provisions of
Rules 144, Rule 144(k) and 701, shares subject to lock-up agreements will not
be eligible for sale until these agreements expire or are waived by Merrill
Lynch. Taking into account the lock-up agreements, and assuming Merrill Lynch
does not release the parties from these agreements, the following shares will
be eligible for sale in the public market at the following times:
. Beginning on the effective date of this offering, shares will be
immediately available for sale in the public market;
. Beginning 90 days after the date of this prospectus, approximately
shares will be eligible for sale under Rules 144 and 701;
. Beginning 180 days after the date of this prospectus, the expiration date
of the lock-up agreements, approximately shares will be eligible for
sale under Rules 144, 144(k) and 701; and
. An additional shares will become eligible for sale under Rule 144
during the period beginning 180 days after the date of this prospectus
through , 2002, upon the expiration of various one-year holding
periods. Shares eligible to be sold by affiliates under Rule 144 are
subject to the volume restrictions below.
Rule 144. In general, under Rule 144 as currently in effect, beginning 90
days after the date of this prospectus, a person, or persons whose shares are
aggregated, who has beneficially owned restricted securities for at least one
year, including the holding period of any prior owner other than an affiliate,
is entitled to sell within any three-month period a number of shares that does
not exceed the greater of (a) 1% of our then outstanding shares of common
stock, approximately shares immediately after this offering, or (b) the
average weekly trading volume of our common stock on the Nasdaq National Market
during the four
65
calendar weeks preceding the date on which notice of sale is filed with the
SEC. Sales under Rule 144 are also subject to manner of sale provisions, notice
requirements and the availability of current public information about us. Under
Rule 144(k), a person who is not deemed to have been one of our affiliates at
any time during the three months preceding a sale, and who has beneficially
owned the shares proposed to be sold for at least two years, may sell these
shares without complying with the manner of sale, public information, volume
limitation or notice provisions of Rule 144.
Rule 701. Beginning 90 days after the effective date of this prospectus,
subject to contractual restrictions, any of our employees, consultants or
advisors who purchased shares from us prior to the closing of this offering
under a written compensatory plan or contract may be entitled to rely on the
resale provisions of Rule 701. Rule 701 permits affiliates to sell their Rule
701 shares under Rule 144 without complying with the holding period
requirements of Rule 144. Rule 701 further provides that persons other than
affiliates may sell shares in reliance on Rule 144 without having to comply
with the holding period, public information, volume limitations or notice
provisions of Rule 144.
Stock plan. As of June 30, 2001, 1,455,003 shares of common stock remain
available for grant under our stock plans and 350,000 shares of common stock
are reserved for future issuance under our 2001 employee stock purchase plan.
No shares have been issued to date under our 2001 employee stock purchase plan.
After the closing of this offering, we intend to file registration
statements under the Securities Act to register shares to be issued under our
stock plans. These registration statements are expected to become effective
immediately upon filing, and shares covered by the registration statements will
then become eligible for sale in the public market. As a result, shares issued
under our 1995 stock option plan, our 2000 stock incentive plan and our 2001
employee stock purchase plan, after the effectiveness of the registration
statements, also will be freely tradeable in the public market, subject to Rule
144 limitations applicable to affiliates, vesting restrictions and expiration
of lock-up agreements.
Lock-up agreements. All of our executive officers and directors and holders
of over 98% of our stock have signed lock-up agreements. Under these
agreements, they have agreed, among other things, not to transfer or dispose of
any shares of our common stock, or securities convertible into shares of common
stock, for a period of 180 days after the date of this prospectus. Transfers or
dispositions can be made sooner with the prior written consent of Merrill
Lynch. This consent may be given at any time without public notice.
66
UNDERWRITING
Merrill Lynch, Pierce, Fenner & Smith Incorporated, Stephens Inc. and First
Union Securities, Inc. are acting as representatives of the underwriters named
below. Subject to the terms and conditions described in a purchase agreement
between us and the underwriters, we have agreed to sell to the underwriters,
and the underwriters severally and not jointly have agreed to purchase from us,
the number of shares listed opposite their names below.
Number
Underwriter of Shares
----------- ---------
Merrill Lynch, Pierce, Fenner & Smith
Incorporated..................................................
Stephens Inc. .....................................................
First Union Securities, Inc. ......................................
----
Total ........................................................
====
Subject to the terms and conditions in the purchase agreement, the
underwriters have agreed to purchase all the shares of our common stock being
sold under the purchase agreement if any of these shares of our common stock
are purchased. If an underwriter defaults, the purchase agreement provides that
the purchase commitments of the nondefaulting underwriter may be increased or
the purchase agreement may be terminated.
We have agreed to indemnify the underwriters against certain liabilities,
including liabilities under the Securities Act, or to contribute to payments
the underwriters may be required to make in respect of those liabilities.
The underwriters are offering the shares of our common stock, subject to
prior sale, when, as and if issued to and accepted by them, subject to approval
of legal matters by their counsel, including the validity of the shares, and
other conditions contained in the purchase agreement, such as the receipt by
the underwriters of officers' certificates and legal opinions. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to
reject orders in whole or in part.
Commissions and Discounts
The representatives have advised us that the underwriters propose initially
to offer the shares of our common stock to the public at the initial public
offering price on the cover page of this prospectus and to dealers at that
price less a concession not in excess of $ per share. The underwriters may
allow, and the dealers may reallow, a discount not in excess of $ per share
to other dealers. After the initial public offering, the public offering price,
concession and discount may be changed.
The following table shows the public offering price, underwriting discount
to be paid by us to the underwriters and the proceeds, before expenses, to us.
This information assumes either no exercise or full exercise by the
underwriters of their overallotment option.
Per Share Without Option With Option
--------- -------------- -----------
Public offering price................. $ $ $
Underwriting discount................. $ $ $
Proceeds, before expenses, to
AgraQuest............................ $ $ $
The expenses of this offering, not including the underwriting discount, are
estimated at $ and are payable by us.
67
Overallotment Option
We have granted an option to the underwriters to purchase up to
additional shares of our common stock at the initial public offering price less
the underwriting discount. The underwriters may exercise this option for
30 days from the date of this prospectus solely to cover any overallotments. If
the underwriters exercise this option, each will be obligated, subject to
conditions contained in the purchase agreement, to purchase a number of
additional shares of our common stock proportionate to that underwriter's
initial amount reflected in the above table.
Reserved Shares
At our request, the underwriters have reserved for sale, at the initial
public offering price, up to shares of our common stock offered hereby to
be sold as part of the underwritten offering to certain individuals and
entities designated by us. We have reserved shares for certain of our employees
and their families and friends and certain individuals and entities with which
we have a business relationship. If these individuals and entities purchase
reserved shares, this will reduce the number of shares available for sale to
the general public. Any reserved shares that are not orally confirmed for
purchase within one day of the pricing of this offering will be offered by the
underwriters to the general public on the same terms as the other shares
offered by this prospectus.
No Sales of Similar Securities
We, our executive officers and directors, and certain existing shareholders
have agreed, with exceptions, not to sell or transfer any shares of our common
stock for 180 days after the date of this prospectus without first obtaining
the written consent of Merrill Lynch. Specifically, we and these other
individuals have agreed not to directly or indirectly:
. offer, pledge, sell or contract to sell any common stock;
. sell any option or contract to purchase any common stock;
. purchase any option or contract to sell any common stock;
. grant any option, right or warrant for the sale of any common stock;
. lend or otherwise dispose of or transfer any common stock;
. request or demand that we file a registration statement related to any
common stock; or
. enter into any swap or other agreement that transfers, in whole or in
part, the economic consequences of ownership of any common stock whether
any such swap or transaction is to be settled by delivery of shares or
other securities, in cash or otherwise.
This lock-up provision applies to shares of our common stock and to
securities convertible into, or exchangeable or exercisable for, or repayable
with, shares of our common stock. Subject to certain exceptions, it also
applies to shares of our common stock owned now or acquired later by the person
executing the agreement or for which the person executing the agreement later
acquires the power of disposition.
Before this offering, there has been no public market for our common stock.
The initial public offering price will be determined through negotiations
between us and Merrill Lynch. In addition to prevailing market conditions, the
factors to be considered in determining the initial public offering price are:
. the valuation multiples of publicly traded companies that the
representatives believe to be comparable to us;
. our financial information;
. the history of, and the prospects for, our company and the industry in
which we compete;
. an assessment of our management, our past and our present operations, and
the prospects for, and timing of, our future revenues;
68
. the present state of our development; and
. the above factors in relation to market values and various valuation
measures of other companies engaged in activities similar to ours.
An active trading market for the shares of our common stock may not
develop. It is also possible that after this offering the shares will not
trade in the public market at or above the initial public offering price.
The underwriters do not expect to sell more than 5% of the shares of our
common stock in the aggregate to accounts over which they exercise
discretionary authority.
Quotation on the Nasdaq National Market
We have applied to list our common stock on the Nasdaq National Market
under the symbol "AGRQ."
Price Stabilization, Short Positions and Penalty Bids
Until the distribution of the shares of our common stock is completed, SEC
rules may limit underwriters and selling group members from bidding for and
purchasing our common stock. However, the representatives may engage in
transactions that stabilize the price of the common stock, such as bids or
purchases to peg, fix or maintain that price.
In connection with the offering, the underwriters may make short sales of
our common stock. Short sales involve the sale by the underwriters at the time
of the offering of a greater number of shares than they are required to
purchase in the offering. Covered short sales are sales made in an amount not
greater than the over-allotment option. The underwriters may close out any
covered short position by either exercising their over-allotment option or
purchasing shares in the open market. In determining the source of shares to
close out the covered short position, the underwriters will consider, among
other things, the price of shares available for purchase in the open market as
compared to the public offering price at which they may purchase the shares
through the over-allotment option.
Naked short sales are sales in excess of the over-allotment option. The
underwriters must close out any naked short position by purchasing shares in
the open market. A naked short position is more likely to be created if the
underwriters are concerned that there may be downward pressure on the price of
the shares in the open market after pricing that could adversely affect
investors who purchase in the offering.
Similar to other purchase transactions, the purchases by the underwriters
to cover syndicate short positions may have the effect of raising or
maintaining the market price of the common stock or preventing or retarding a
decline in the market price of the common stock. As a result, the price of our
common stock may be higher than it would otherwise be in the absence of these
transactions.
The representatives may also impose a penalty bid on underwriters and
selling group members. This means that if the representatives purchase shares
of our common stock in the open market to reduce the underwriter's short
position or to stabilize the price of such shares, they may reclaim the amount
of the selling commission from the underwriters and selling group members who
sold those shares. The imposition of a penalty bid may also affect the price
of the shares of our common stock in that it discourages resales of those
shares.
Neither we nor any of the underwriters make any representation or
prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of the common stock. In
addition, neither we nor any of the underwriters make any representation that
the representatives or the lead managers will engage in these transactions or
that these transactions, once commenced, will not be discontinued without
notice.
69
Electronic Distribution
Merrill Lynch will be facilitating Internet distribution for this offering
to some of its Internet subscription customers. Merrill Lynch intends to
allocate a limited number of shares for sale to its online brokerage customers.
An electronic prospectus is available on the Internet Web site maintained by
Merrill Lynch. Other than the prospectus in electronic format, the information
on the Merrill Lynch Web site is not a part of this prospectus.
Other Relationships
Some of the underwriters and their affiliates have engaged in, and may in
the future engage in, investment banking and other commercial dealings in the
ordinary course of business with us. They have received customary fees and
commissions for these transactions.
As of June 30, 2001, Stephens Group, Inc., the parent company of Stephens
Inc., one of the underwriters, held 781,250 shares of our Series E preferred
stock through Stephens-AgraQuest LLC, a limited liability company controlled by
Stephens Group, Inc. These shares were purchased in April 2000 at $3.20 per
share and represent approximately 4.2% of our outstanding equity securities
prior to this offering.
70
LEGAL MATTERS
The validity of the common stock offered by this prospectus will be passed
upon for us by Morrison & Foerster llp, Sacramento, California. Certain legal
matters will be passed on for the underwriters by Sidley Austin Brown & Wood
llp, New York, New York.
EXPERTS
Ernst & Young LLP, independent auditors, have audited our consolidated
financial statements at December 31, 1999 and 2000, and for each of the three
years in the period ended December 31, 2000, as set forth in their report. We
have included our consolidated financial statements in this prospectus and
elsewhere in the registration statement in reliance on Ernst & Young LLP's
report, given on their authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the Securities and Exchange Commission, or the SEC, in
Washington, D.C. a registration statement on Form S-1 under the Securities Act
with respect to the common stock offered in this prospectus. This prospectus,
filed as part of the registration statement, does not contain all of the
information set forth in the registration statement and its exhibits and
schedules, portions of which have been omitted as permitted by the rules and
regulations of the SEC. For further information about us and our common stock,
we refer you to the registration statement and to its exhibits and schedules.
Statements in this prospectus about the contents of any contract, agreement or
other document that has been filed as an exhibit to the registration statement
are qualified by reference to the copy of that contract, agreement or document
that has been filed. Anyone may inspect the registration statement and its
exhibits and schedules without charge at the public reference facilities the
SEC maintains at 450 Fifth Street, N.W., Washington, D.C. 20549. You may obtain
copies of all or any part of these materials from the SEC upon the payment of
certain fees prescribed by the SEC. You may obtain information on the operation
of the Public Reference Room by calling the SEC at 1-800-SEC-0330. You may also
inspect these reports and other information without charge at a Web site
maintained by the SEC. The address of this site is http://www.sec.gov.
Upon completion of this offering, we will become subject to the
informational requirements of the Exchange Act and will be required to file
reports, proxy statements and other information with the SEC. You will be able
to inspect and copy these reports, proxy statements and other information at
the public reference facilities maintained by the SEC and at the SEC's regional
offices at the addresses noted above. You also will be able to obtain copies of
this material from the Public Reference Section of the SEC as described above,
or inspect them without charge at the SEC's Web site. We have applied for
quotation of our common stock on the Nasdaq National Market. If we receive
approval for quotation on the Nasdaq National Market, then you will be able to
inspect reports, proxy and information statements and other information
concerning us at the National Association of Securities Dealers, Inc. at 1735 K
Street, N.W., Washington, D.C. 20006.
71
AGRAQUEST, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Report of Ernst & Young LLP, Independent Auditors....................... F-2
Consolidated balance sheets as of December 31, 1999 and 2000 (audited)
and as of June 30, 2001 (unaudited).................................... F-3
Consolidated statements of operations for each of the three years in the
period ended December 31, 2000 (audited) and for the six months ended
June 30, 2000 and 2001 (unaudited)..................................... F-4
Consolidated statements of changes in convertible preferred stock,
common stock and other stockholders' equity (deficit) for each of the
three years in the period ended December 31, 2000 (audited) and for the
six months ended June 30, 2001 (unaudited)............................. F-5
Consolidated statements of cash flows for each of the three years in the
period ended December 31, 2000 (audited) and for the six months ended
June 30, 2000 and 2001 (unaudited)..................................... F-6
Notes to consolidated financial statements.............................. F-7
F-1
REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
The Board of Directors and Stockholders
AgraQuest, Inc.
We have audited the accompanying consolidated balance sheets of AgraQuest,
Inc. as of December 31, 1999 and 2000, and the related consolidated statements
of operations, changes in convertible preferred stock, common stock and other
stockholders' equity (deficit) and cash flows for each of the three years in
the period ended December 31, 2000. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the consolidated financial position of AgraQuest,
Inc. at December 31, 1999 and 2000, and the consolidated results of its
operations and its cash flows for each of the three years in the period ended
December 31, 2000, in conformity with accounting principles generally accepted
in the United States.
/s/ Ernst & Young LLP
Sacramento, California
January 19, 2001
F-2
AGRAQUEST, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
Pro Forma
December 31, Stockholders'
------------------ June 30, Equity at
1999 2000 2001 June 30, 2001
-------- -------- -------- -------------
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents........ $ 2,849 $ 12,518 $ 6,359
Accounts receivable.............. 95 261 146
Other receivables................ -- 1,033 1,064
Inventories...................... 204 1,198 1,417
Other current assets............. 23 68 91
-------- -------- --------
Total current assets........... 3,171 15,078 9,077
Plant and equipment................ 2,079 9,181 9,838
Other assets....................... 186 186 440
-------- -------- --------
Total assets................... $ 5,436 $ 24,445 $ 19,355
======== ======== ========
LIABILITIES AND STOCKHOLDERS'
EQUITY (DEFICIT)
Current liabilities:
Accounts payable................. $ 265 $ 502 $ 389
Accrued liabilities.............. 457 731 384
Deferred revenue................. -- 100 53
Current portion of notes
payable......................... 139 219 228
Current portion of capital lease
obligations..................... 96 104 74
-------- -------- --------
Total current liabilities...... 957 1,656 1,128
Long-term liabilities:
Seller promissory note........... -- 5,000 5,000
Notes payable, net of current
portion......................... 253 295 162
Capital lease obligations, net of
current portion................. 116 45 44
-------- -------- --------
Total liabilities.............. 1,326 6,996 6,334
Commitments and contingencies
(Notes 1 and 6)
Convertible preferred stock--16,000
shares authorized, $0.001 par
value; 9,676 shares issued and
outstanding at December 31, 1999,
14,904 shares issued and
outstanding at December 31, 2000
and June 30, 2001, none issued and
outstanding pro forma (aggregate
liquidation preference of $41,137
and $42,532 at December 31, 2000
and June 30, 2001)................ 17,252 40,858 42,239 $ --
Stockholders' equity (deficit):
Common stock--26,000 shares
authorized, $0.001 par value;
3,348, 3,553 and 3,688 shares
issued and outstanding at
December 31, 1999 and 2000 and
June 30, 2001, 18,592 shares
issued and outstanding
pro forma....................... 567 1,336 2,192 44,431
Deferred stock option
compensation.................... -- (454) (952) (952)
Accumulated deficit.............. (13,709) (24,291) (30,458) (30,458)
-------- -------- -------- --------
Total stockholders' equity
(deficit)..................... (13,142) (23,409) (29,218) $ 13,021
-------- -------- -------- ========
Total liabilities and
stockholders' equity
(deficit)..................... $ 5,436 $ 24,445 $ 19,355
======== ======== ========
See accompanying notes.
F-3
AGRAQUEST, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Six Months
Year Ended December 31, Ended June 30,
-------------------------- ----------------
1998 1999 2000 2000 2001
------- ------- -------- ------- -------
(Unaudited)
Revenues:
Product sales................... $ -- $ -- $ 502 $ -- $ 428
Research revenue................ 110 77 218 75 117
------- ------- -------- ------- -------
Total revenues................. 110 77 720 75 545
Operating costs and expenses:
Cost of product sales........... -- -- 502 -- 484
Manufacturing plant start-up
costs.......................... -- -- -- -- 295
Research and development........ 3,090 4,468 6,300 3,558 2,651
Selling, general and
administrative................. 836 1,749 2,914 1,191 1,777
Stock option compensation (Note
8)............................. 15 12 224 14 301
------- ------- -------- ------- -------
Total operating costs and
expenses...................... 3,941 6,229 9,940 4,763 5,508
------- ------- -------- ------- -------
Loss from operations............. (3,831) (6,152) (9,220) (4,688) (4,963)
Interest income.................. 190 155 218 85 241
Interest and other expense....... (20) (87) (84) (34) (50)
------- ------- -------- ------- -------
Net loss......................... (3,661) (6,084) (9,086) (4,637) (4,772)
Preferred stock accretion........ (341) (810) (1,496) (642) (1,395)
------- ------- -------- ------- -------
Net loss applicable to common
stockholders.................... $(4,002) $(6,894) $(10,582) $(5,279) $(6,167)
======= ======= ======== ======= =======
Basic and diluted net loss per
share applicable to common
stockholders.................... $ (1.30) $ (2.20) $ (3.07) $ (1.55) $ (1.70)
======= ======= ======== ======= =======
Shares used in computing basic
and diluted net loss per share
applicable to common
stockholders.................... 3,068 3,140 3,451 3,399 3,620
======= ======= ======== ======= =======
Pro forma basic and diluted net
loss per share applicable to
common stockholders
(unaudited)..................... $ (0.61) $ (0.26)
======== =======
Shares used in computing pro
forma basic and diluted net loss
per share applicable to common
stockholders (unaudited)........ 14,802 18,524
======== =======
See accompanying notes.
F-4
AGRAQUEST, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK,
COMMON STOCK AND OTHER STOCKHOLDERS' EQUITY (DEFICIT)
(In thousands)
Convertible
Preferred
Stock Common Stock Deferred Total
-------------- ------------- Stock Option Accumulated Stockholders'
Shares Amount Shares Amount Compensation Deficit Equity (Deficit)
------ ------- ------ ------ ------------ ----------- ----------------
Balance at December 31,
1997................... 3,137 $ 3,149 3,068 $ 434 $ -- $ (2,813) $ (2,379)
Sale of Series C
preferred stock, net of
issuance costs of $85.. 3,524 5,906 -- -- -- -- --
Fair value of options
granted to non-
employees.............. -- -- -- 15 -- -- 15
Preferred stock
accretion.............. -- 341 -- -- -- (341) (341)
Net loss................ -- -- -- -- -- (3,661) (3,661)
------ ------- ----- ------ ----- -------- --------
Balance at December 31,
1998................... 6,661 9,396 3,068 449 -- (6,815) (6,366)
Sale of Series D
preferred stock, net of
issuance costs of $39.. 3,015 7,046 -- -- -- -- --
Exercise of employee
stock options.......... -- -- 280 98 -- -- 98
Fair value of options
granted to non-
employees.............. -- -- -- 20 -- -- 20
Preferred stock
accretion.............. -- 810 -- -- -- (810) (810)
Net loss................ -- -- -- -- -- (6,084) (6,084)
------ ------- ----- ------ ----- -------- --------
Balance at December 31,
1999................... 9,676 17,252 3,348 567 -- (13,709) (13,142)
Sale of Series E
preferred stock, net of
issuance costs of $35.. 2,252 7,168 -- -- -- -- --
Exercise of employee
stock options.......... -- -- 205 91 -- -- 91
Fair value of stock
options granted to non-
employees.............. -- -- -- 150 -- -- 150
Deferred stock option
compensation........... -- -- -- 528 (528) -- --
Amortization of deferred
stock option
compensation........... -- -- -- -- 74 -- 74
Sale of Series F
preferred stock, net of
issuance costs of $23.. 2,976 14,942 -- -- -- -- --
Preferred stock
accretion.............. -- 1,496 -- -- -- (1,496) (1,496)
Net loss................ -- -- -- -- -- (9,086) (9,086)
------ ------- ----- ------ ----- -------- --------
Balance at December 31,
2000................... 14,904 40,858 3,553 1,336 (454) (24,291) (23,409)
Exercise of employee
stock options
(unaudited)............ -- -- 135 57 -- -- 57
Fair value of stock
options granted to non-
employees (unaudited).. -- -- -- 89 -- -- 89
Additional Series F
issuance costs
(unaudited)............ -- (14) -- -- -- -- --
Deferred stock option
compensation
(unaudited)............ -- -- -- 710 (710) -- --
Amortization of deferred
stock option
compensation
(unaudited)............ -- -- -- -- 212 -- 212
Preferred stock
accretion (unaudited).. -- 1,395 -- -- -- (1,395) (1,395)
Net loss (unaudited).... -- -- -- -- -- (4,772) (4,772)
------ ------- ----- ------ ----- -------- --------
Balance at June 30, 2001
(unaudited)............ 14,904 $42,239 3,688 $2,192 $(952) $(30,458) $(29,218)
====== ======= ===== ====== ===== ======== ========
See accompanying notes.
F-5
AGRAQUEST, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
(In thousands)
Six Months
Year Ended December 31, Ended June 30,
------------------------- ----------------
1998 1999 2000 2000 2001
------- ------- ------- ------- -------
(Unaudited)
Operating activities
Net loss......................... $(3,661) $(6,084) $(9,086) $(4,637) $(4,772)
Adjustments to reconcile net loss
to net cash used in operating
activities:
Depreciation and amortization.. 61 184 296 143 147
Stock option and stock warrant
expenses...................... 15 20 224 14 301
Changes in operating assets and
liabilities:
Accounts receivable............ (16) (79) (166) 88 115
Other receivables.............. -- -- (1,033) -- (31)
Inventories.................... -- (204) (994) (1,361) (219)
Other assets................... (26) (136) (45) (22) (23)
Accounts payable............... 132 77 237 275 (113)
Accrued liabilities............ 58 327 274 (292) (347)
Deferred revenue............... -- -- 100 75 (47)
------- ------- ------- ------- -------
Net cash used in operating
activities...................... (3,437) (5,895) (10,193) (5,717) (4,989)
Investing activities
Purchases of plant and
equipment....................... (701) (1,122) (2,357) (120) (780)
Financing activities
Proceeds from issuance of notes
payable......................... 459 -- 300 -- --
Repayment of notes payable....... (38) (142) (178) (71) (125)
Repayment of capital lease
obligations..................... (9) (92) (104) (51) (54)
Proceeds from sale of common
stock........................... -- 98 91 3 57
Proceeds from sale of convertible
preferred stock................. 5,906 7,046 22,110 7,168 --
Increase in other non-current
assets.......................... -- -- -- -- (268)
------- ------- ------- ------- -------
Net cash provided by (used in)
financing activities............ 6,318 6,910 22,219 7,049 (390)
------- ------- ------- ------- -------
Net increase (decrease) in cash
and cash equivalents............ 2,180 (107) 9,669 1,212 (6,159)
Cash and cash equivalents at
beginning of period............. 776 2,956 2,849 2,849 12,518
------- ------- ------- ------- -------
Cash and cash equivalents at end
of period....................... $ 2,956 $ 2,849 $12,518 $ 4,061 $ 6,359
======= ======= ======= ======= =======
Supplementary disclosures of cash
flow information and non-cash
transactions:
Cash paid for interest........... $ 20 $ 79 $ 84 $ 34 $ 271
======= ======= ======= ======= =======
Borrowings for the purchase of
plant and equipment............. $ 56 $ 252 $ 5,041 $ 41 $ 24
======= ======= ======= ======= =======
See accompanying notes.
F-6
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
As of December 31, 1999 and 2000 and for each of the
three years in the period ended December 31, 2000
(information as of June 30, 2000 and 2001 and for the six months then ended is
unaudited)
1. Business and Significant Accounting Policies
Description of Business and Plan of Operations
AgraQuest, Inc. (the "Company") was incorporated under the laws of the State
of Delaware on January 24, 1995. The Company is focused on discovering,
developing, manufacturing and marketing effective, safe and environmentally
friendly pest management products for agricultural and institutional and home
markets.
The Company has devoted substantially all of its efforts towards research
and development activities and has recently commenced marketing and sales
efforts of its first product. The Company is subject to a number of risks and
uncertainties, including that: the Company may not be able to identify or
commercialize product candidates, obtain regulatory approvals or develop
adequate sales and marketing capabilities or distribution relationships; the
markets for pest management products are intensely competitive; the Company
depends on its principal management and scientific personnel; and the Company
may not be able to protect its patents and proprietary rights. The Company has
financed its operations primarily through the sale of preferred stock and
various debt financing arrangements. Management believes that additional
funding will be needed to finance planned operations. However, management has
the intent, and believes it has the ability, to delay or reduce expenditures so
as not to require additional financial resources if such resources are not
available. If additional funding is not available, management believes that
available resources will provide sufficient funding to enable the Company to
meet its obligations at least through December 31, 2001.
Basis of Presentation
The consolidated financial statements have been prepared in accordance with
accounting principles generally accepted in the United States and include the
accounts of the Company and its subsidiary, AgraQuest de Mexico, S.A. de C.V.
Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
Cash Equivalents
The Company considers all highly liquid investments with an original
maturity from the date of purchase of three months or less to be cash
equivalents for the purpose of balance sheet and statement of cash flows
presentation. Cash equivalents consist primarily of funds invested in money
market accounts at the balance sheet dates. The carrying value of cash and
equivalents approximates market value at the balance sheet dates.
Concentrations of Risk
Financial instruments which subject the Company to potential credit risk
consist of its cash equivalents and accounts receivable. The Company invests
with high credit quality financial institutions. The Company believes the
financial risks associated with these financial instruments are minimal.
F-7
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The Company's Serenade product has accounted for all of the Company's
product sales for the year ended December 31, 2000 and for the six months ended
June 30, 2001. For the year ended December 31, 2000, four distributors
accounted for 34%, 25%, 17% and 13% of total product sales. As of December 31,
2000, two of these distributors represent 48% and 37% of total accounts
receivable. For the six months ended June 30, 2001, three distributors
accounted for 39%, 23% and 21% of total product sales. In the opinion of
management, these distributors represent the leading national agricultural
distributors in the United States in the Company's markets. The Company
generally does not require collateral. The Company may provide reserves for
potential credit losses but has not experienced significant losses to date.
Inventories
Inventories are stated at the lower of cost, determined on a first-in,
first-out basis, or market value. At December 31, 2000, inventory consisted of
the following: raw materials of $156,000, work-in-process of $325,000 and
finished goods of $717,000.
Plant and Equipment
Plant and equipment are stated at cost, net of accumulated depreciation and
amortization. Depreciation and amortization are calculated on a straight-line
basis over the lesser of the estimated useful lives of the assets or the lease
term. The estimated useful lives of the Company's assets are as follows:
Manufacturing plant and equipment 3 to 25 years
Laboratory equipment and pilot plant 4 to 10 years
Leasehold improvements 5 to 10 years
Office furniture and equipment 3 to 10 years
Vehicles 3 to 5 years
Revenue Recognition
The Company recognizes revenue from product sales upon shipment to its
distributors, unless contractual obligations, acceptance provisions or other
contingencies exist. If such obligations or provisions exist, revenue is
recognized after such obligations or provisions are fulfilled or expire.
Distributors do not have price protection or return rights. The Company
generates research revenues from research and development activities under
contracts with other entities. The Company recognizes revenue from "best
efforts" research and development contracts as work is performed. If, however,
the contracts provide for specific milestones or deliverables, the Company
recognizes revenue upon the achievement of such milestones or upon delivery.
Funding received in advance of work performed, including up-front payments, is
recorded as deferred revenue. Costs incurred under these "best efforts"
research and development contracts are expensed to operations as incurred and
included as a component of research and development expense in accordance with
Statement of Financial Accounting Standards No. 2, "Accounting for Research and
Development Costs." The Company may also receive payments under strategic
collaboration agreements as the collaborators or their sublicensees achieve
product development milestones as well as royalty payments based on sales of
products that incorporate its proprietary technology. The Company will
recognize any future milestone payments or royalty revenues as earned.
In December 2000, the Company entered into an agreement with Maxygen, Inc.
under which the Company granted Maxygen a right to access a definitive number
of strains of microorganisms from the Company's proprietary database for uses
other than for the development of biopesticides. Maxygen paid an up-front
collection fee and may make future milestone payments based on its progress of
product development and commercialization of products from these
microorganisms. The up-front collection fee is being recognized ratably as the
Company delivers these microorganisms to Maxygen.
F-8
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The Company has deferred the recognition of revenue for some sales
transactions that provide for payment terms of relatively longer duration.
During the six months ended June 30, 2001, the Company deferred recognition of
such revenue in the amount $334,000. For transactions with such longer payment
terms, the Company's policy is to recognize revenue upon the earlier of cash
received or the original invoice due date, assuming collectibility is deemed
probable at that date. At June 30, 2001, transactions with such longer payment
terms have original invoice due dates in August 2001.
Shipping and Handling Costs
Amounts billed for shipping and handling are included as a component of
product sales. Related costs for shipping and handling have been included as a
component of cost of product sales.
Research and Development
Research and development costs are expensed to operations as incurred in
accordance with Statement of Financial Accounting Standards No. 2, "Accounting
for Research and Development Costs." The cost of product manufactured in pre-
production batches yielding saleable quantities of Serenade has been included
in inventories. These quantities have been recorded at the lower of cost or net
realizable value.
Advertising
The Company expenses advertising costs as incurred. Advertising costs for
the year ended December 31, 2000 and for the six months ended June 30, 2001
were $357,000 and $209,000. No such costs were incurred prior to fiscal 2000.
Stock Option Compensation
As permitted under the provisions of Statement of Financial Accounting
Standards No. 123, "Accounting for Stock-Based Compensation" ("SFAS 123"), for
stock options granted to its employees, the Company has elected to account for
stock-based compensation using the intrinsic value method prescribed by
Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to
Employees" and related interpretations ("APB 25"). Under the intrinsic value
method, compensation cost is the excess, if any, of the fair value of the stock
at the grant date, or other measurement date, over the amount an employee must
pay to acquire the stock.
Segment Disclosures
The Company operates in one segment, the development, manufacture and
marketing of effective, safe and environmentally friendly pest management
products for agricultural and institutional and home markets. For the year
ended December 31, 2000, sales to the U.S. and Chile accounted for 75% and 25%
of total product sales. For the six months ended June 30, 2001, the U.S.
accounted for 100% of total product sales.
Recent Accounting Pronouncements
In June 1998, the Financial Accounting Standards Board issued Statement No.
133, "Accounting for Derivative Instruments and Hedging Activities" ("SFAS
133") which, as amended, is required to be adopted in years beginning after
June 15, 2000. Because the Company does not use derivative instruments, the
adoption of SFAS 133 did not have an effect on the results of operations,
financial position or cash flows of the Company.
F-9
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Unaudited Interim Financial Information
The financial information at June 30, 2001 and for the six months ended June
30, 2000 and 2001 is unaudited but in the opinion of management includes all
adjustments, consisting of normal recurring adjustments, which the Company
considers necessary for a fair presentation of the financial position at such
date and the operating results and cash flows for those periods. Results of the
June 30, 2001 interim period are not necessarily indicative of the results for
the entire fiscal year or future periods.
2. Unaudited Pro Forma Stockholders' Equity and Net Loss Per Share
The Board of Directors has authorized management of the Company to file a
registration statement with the Securities and Exchange Commission permitting
the Company to sell shares of its common stock to the public. If the initial
public offering contemplated by the Company is consummated, all of the
preferred stock outstanding will automatically be converted into shares of
common stock on a one-for-one basis. Unaudited pro forma stockholders' equity
at June 30, 2001 is set forth in the accompanying consolidated balance sheet
and reflects the adjustment for the assumed conversion of preferred stock
outstanding at June 30, 2001. Upon the completion of this offering, the Company
will be authorized to issue up to 66,000,000 shares of capital stock, $0.001
par value per share. Of these authorized shares, 60,000,000 shares will be
designated as common stock and 6,000,000 shares will be designated as preferred
stock.
Basic and diluted net loss per share applicable to common stockholders have
been computed using the weighted-average number of shares of common stock
outstanding during the period. Pro forma basic and diluted net loss per share
applicable to common stockholders, as presented in the statements of
operations, have been computed as described above and also give effect to the
conversion of the convertible preferred stock (using the if-converted method)
from the original date of issuance. To date, the Company has not had any
issuances of shares for nominal consideration as that term is used in the
Securities and Exchange Commission's Staff Accounting Bulletin No. 98,
"Earnings Per Share."
F-10
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The following table presents the calculation of basic and diluted net loss
per share and pro forma basic and diluted net loss per share (in thousands,
except per share amounts):
Six Months
Year Ended December 31, Ended June 30,
-------------------------- ----------------
1998 1999 2000 2000 2001
------- ------- -------- ------- -------
(Unaudited)
Numerator used for basic and
diluted net loss per share
applicable to common
stockholders................... $(4,002) $(6,894) $(10,582) $(5,279) $(6,167)
======= ======= ======== ======= =======
Denominator used for basic and
diluted net loss per share
applicable to common
stockholders--weighted average
common shares outstanding...... 3,068 3,140 3,451 3,399 3,620
======= ======= ======== ======= =======
Basic and diluted net loss per
share applicable to common
stockholders................... $ (1.30) $ (2.20) $ (3.07) $ (1.55) $ (1.70)
======= ======= ======== ======= =======
Potentially dilutive securities
excluded from diluted net loss
per share applicable to common
stockholders computation
because they are anti-
dilutive....................... 8,190 11,156 17,139 13,784 17,368
======= ======= ======== ======= =======
Numerator used for pro forma
basic and diluted net loss per
share applicable to common
stockholders (unaudited)....... $ (9,086) $(4,772)
======== =======
Shares used in computing pro
forma basic and diluted net
loss per share applicable to
common stockholders
(unaudited):
Shares used above............. 3,451 3,620
Pro forma adjustments to
reflect weighted effect of
the assumed conversion of
preferred stock (unaudited).. 11,351 14,904
-------- -------
14,802 18,524
======== =======
Pro forma basic and diluted net
loss per share applicable to
common stockholders
(unaudited).................... $ (0.61) $ (0.26)
======== =======
3. Other Receivables
Other receivables consist of the following at December 31, 2000 (in
thousands):
VAT refund........................................................... $ 836
Refund due from supplier............................................. 164
Other................................................................ 33
------
$1,033
======
F-11
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
4. Plant and Equipment
Plant and equipment consists of the following (in thousands):
December 31,
--------------
1999 2000
------ ------
Land......................................................... $ -- $1,237
Manufacturing plant and equipment............................ -- 5,992
Laboratory equipment and pilot plant......................... 1,672 1,751
Leasehold improvements....................................... 562 564
Office furniture and equipment............................... 117 175
Vehicles..................................................... 13 43
------ ------
2,364 9,762
Less accumulated depreciation and amortization............... (285) (581)
------ ------
$2,079 $9,181
====== ======
The Company has granted to third parties interests in specific plant and
equipment as part of certain financing arrangements (Note 5).
In December 2000, the Company purchased a manufacturing facility in
Tlaxcala, Mexico for $7.0 million. A portion of the purchase price was financed
with a promissory note from the seller (Note 5). During the six months ended
June 30, 2001, the Company incurred costs for one-time activities related to
opening this new facility as well as costs required to ready the purchased
long-lived assets for their intended use. As of June 30, 2001, activities
necessary to prepare this facility for its intended use were in progress.
Manufacturing plant start-up costs were $295,000 for the six months ended
June 30, 2001 and represents expenses incurred through June 30, 2001 in
connection with one-time activities related to opening the new manufacturing
facility in Tlaxcala, Mexico. These costs have been accounted for in accordance
with Statement of Position 98-5, "Reporting on the Costs of Start-up
Activities." Costs associated with start-up activities are primarily related to
the operating costs incurred during the pre-production period which include a
portion of salary-related expenses for employees in Mexico, travel costs for
the implementation team, consulting fees and routine maintenance costs. These
start-up costs exclude expenditures relating to constructing and developing
long-lived assets and other necessary activities to prepare these assets for
their intended use.
Of total interest costs of $271,000 incurred during the six months ended
June 30, 2001, $225,000 has been capitalized as part of the Company's new
manufacturing facility in accordance with Statement of Financial Accounting
Standards No. 34, "Capitalization of Interest Cost."
5. Notes Payable and Capital Lease Obligations
In December 2000, the Company purchased a manufacturing facility in
Tlaxcala, Mexico for $7.0 million. A portion of the purchase price, $5.0
million, has been financed with a promissory note from the seller which bears
interest at a rate of 9.0% per annum. The maturity date of this note is the
earlier of: December 2002, the receipt of proceeds from an underwritten initial
public offering, the receipt of proceeds from a private placement financing
specifically designated for the financing of the facility or debt financing of
the facility.
F-12
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Other notes payable consist of the following (in thousands):
December
31,
------------
1999 2000
----- -----
Note payable, bearing interest at an effective rate of 13.5%
per annum, payable through July 2002, collateralized by
equipment with a net book value of $388 at December 31,
2000........................................................ $ 345 $ 496
Note payable, bearing interest at 19.4% per annum, payable
through October 2001, collateralized by equipment with a net
book value of $38 at December 31, 2000...................... 47 18
----- -----
392 514
Less current portion......................................... (139) (219)
----- -----
$ 253 $ 295
===== =====
As of December 31, 2000, aggregate contractual future principal payments by
year on notes payable are due as follows: 2001-$219,000; 2002-$5.2 million; and
2003-$59,000.
In accordance with Statement of Financial Accounting Standard No. 13,
"Accounting for Leases," the Company accounts for certain equipment acquired
under financing arrangements as capital leases. This equipment is included in
plant and equipment and related amortization is included in depreciation
expense. The cost of this equipment was $317,000 and $358,000 and the related
accumulated amortization was $38,000 and $67,000 as of December 31, 1999 and
2000.
The Company's aggregate commitment under these lease arrangements as of
December 31, 2000 is as follows (in thousands):
2001.................................................................. $ 126
2002.................................................................. 24
2003.................................................................. 6
-----
Total minimum payment required........................................ 156
Less: amount representing interest.................................... (7)
-----
Present value of future payments...................................... 149
Less: current portion................................................. (104)
-----
$ 45
=====
The carrying values of these obligations approximate their fair values as of
December 31, 1999 and 2000. The fair value of long-term debt is estimated based
on current interest rates available to the Company for debt instruments with
similar terms, degrees of risk and remaining maturities.
6. Commitments and Contingencies
Lease Commitments
The Company has executed a 10 year lease agreement on a building in Davis,
California for office, laboratory and pilot plant space. The lease agreement
provides for annual minimum lease payments of approximately $194,000 which
commenced upon completion of construction in March 1999. Rental expense charged
to operations for all operating leases was approximately $100,000, $208,000 and
$244,000 for the years ended December 31, 1998, 1999 and 2000 and $126,000 for
the six months ended June 30, 2001.
F-13
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Contingencies
The Company may from time to time become a party to various legal
proceedings arising in the ordinary course of its business. The Company is not
currently subject to any legal proceeding.
7. Convertible Preferred Stock
The Company's convertible preferred stock is classified as mezzanine
financing, outside of permanent equity, due to the liquidation rights upon a
change in control, as this condition is not solely within the control of the
Company. Given the liquidation rights of the Company's convertible preferred
stock, these securities have been accounted for as if they were redeemable
preferred stock. As such, the redemption value of the convertible preferred
stock is its liquidation preference, and the carrying value of the convertible
preferred stock is adjusted to its redemption amount at each balance sheet date
through corresponding debits and credits to accumulated deficit and convertible
preferred stock, respectively.
At December 31, 2000, the Company was authorized to issue up to 16,000,000
shares of convertible preferred stock, issuable in series, with the rights and
preferences of each designated series to be determined by the Board of
Directors. The outstanding shares of convertible preferred stock automatically
convert into common stock upon the closing of an underwritten public offering
of common stock provided the offering meets certain minimum proceeds
requirements.
Convertible preferred stock as of December 31, 2000 is as follows (in
thousands):
Shares
Issued and Gross Net
Designated Outstanding Proceeds Proceeds
---------- ----------- -------- --------
Series A............................ 150 138 $ 97 $ 91
Series B............................ 3,000 2,999 3,149 3,058
Series C............................ 3,575 3,524 5,991 5,906
Series D............................ 3,025 3,015 7,085 7,046
Series E............................ 3,250 2,252 7,203 7,168
Series F............................ 3,000 2,976 14,965 14,942
------ ------ ------- -------
16,000 14,904 $38,490 $38,211
====== ====== ======= =======
Each share of Series A, B, C, D, E and F convertible preferred stock is
convertible, at the option of the holder, into common stock on a one-for-one
basis, subject to certain adjustments for dilution, if any, resulting from
future stock issuances.
The Series A, B, C, D, E and F convertible preferred stockholders are
entitled to noncumulative dividends, before and in preference to any dividends
paid on common stock. Dividends will be paid only when and if declared by the
Board of Directors. No dividends have been declared through December 31, 2000.
Beginning on October 1, 2002 for Series C, October 1, 2003 for Series D,
October 1, 2004 for Series E and October 1, 2005 for Series F, cumulative
dividends will accrue at rates from 8% to 12% per annum and will be payable,
quarterly in cash, beginning on January 1, 2003 for Series C, January 1, 2004
for Series D, January 1, 2005 for Series E and January 1, 2006 for Series F.
The liquidation preference of Series A, B, C, D, E and F convertible
preferred stock is nonparticipating and the stockholders are entitled to
receive $0.70; $1.05; $1.70 plus 8% of this amount per annum from the date of
issuance; $2.35 plus 8% of this amount per annum from the date of issuance;
$3.20 plus 8% of this amount per annum from the date of issuance; and $5.00
plus 8% of this amount per annum from the date of
F-14
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
issuance, respectively. As of June 30, 2001, the aggregate liquidation
preference was $42.5 million. The aggregate liquidation preference was
calculated based on the contractual amount per share to be received by each
stockholder at the time of a qualifying liquidation event. For Series A and B
convertible preferred stockholders, this amount represents the original
purchase price of the stock. For Series C, D, E and F convertible preferred
stockholders, this amount represents the original purchase price of the stock
plus 8% of the original purchase price per annum from the date of issuance.
The Series A, B, C, D, E and F convertible preferred stockholders have
voting rights equal to the shares of common stock issuable upon conversion.
8. Stockholders' Equity (Deficit)
Common Stock
As of December 31, 2000, the Company has reserved shares of common stock for
the conversion of preferred stock, the exercise of warrants, and the issuance
of options granted under the Company's stock option plans as follows (in
thousands):
Subsequent to December 31, 2000, an additional 1,000,000 shares of the
Company's common stock has been reserved for future issuance pursuant to its
2000 stock incentive plan.
Warrants
In December 1998, in connection with entering into a credit agreement, the
Company issued warrants, which were immediately exercisable, to purchase 39,000
shares of common stock at an exercise price of $1.70 per share. These warrants
expire in December 2008. The Company determined the fair value of these
warrants using the Black-Scholes option pricing model assuming a fair value of
the Company's common stock at the date of issuance of $0.35 per share,
volatility factor of 0.75, risk-free interest rate of 5.4%, contractual life of
10 years and no dividend yield. The fair value of $8,000 was fully amortized in
1999 as interest expense.
Stock Option Plans
The Company established a stock option plan in 1995 under which employees,
consultants and directors may be granted Incentive Stock Options ("ISOs") or
Nonstatutory Stock Options ("NSOs") to purchase shares of the Company's common
stock. This plan permits ISOs to be granted at an exercise price not less than
the fair value of the Company's stock on the date of grant and NSOs at an
exercise price not less than 85% of the fair value of the Company's common
stock on the date of grant. Options granted under this plan generally expire 10
years from the date of grant. Options generally vest 20% on the first
anniversary from the date of grant and 1/20 per quarter thereafter, however,
options may be granted with different vesting terms as determined by the Board
of Directors. A total of 2,500,000 shares of common stock have been authorized
for issuance pursuant to this stock option plan.
In December 2000, the Company adopted the 2000 stock incentive plan, which
was amended and restated in January 2001. The Company originally reserved
1,000,000 shares of common stock pursuant to this plan and an additional
1,000,000 shares upon its amendment and restatement.
F-15
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The Company adopted the 2001 non-employee director stock program as part of
the 2000 stock incentive plan. In addition, the Company adopted the 2001
employee stock purchase plan and has reserved 350,000 shares under this plan.
These programs will become effective as of the effective date of the initial
public offering.
A summary of stock option activity is as follows (in thousands, except per
share data):
Options Outstanding
-------------------
Weighted-
Average
Number of Exercise
Shares Price
--------- ---------
Balance as of December 31, 1997............................. 984 $0.35
Granted................................................... 506 0.35
-----
Balance as of December 31, 1998............................. 1,490 0.35
Granted................................................... 234 0.35
Exercised................................................. (280) 0.35
Forfeited................................................. (3) 0.35
-----
Balance as of December 31, 1999............................. 1,441 0.35
Granted................................................... 1,021 1.53
Exercised................................................. (205) 0.44
Forfeited................................................. (60) 0.47
-----
Balance as of December 31, 2000............................. 2,197 0.89
Granted (unaudited)....................................... 525 4.19
Exercised (unaudited)..................................... (135) 0.43
Forfeited (unaudited)..................................... (162) 0.43
-----
Balance as of June 30, 2001 (unaudited)..................... 2,425 1.66
=====
The weighted-average remaining contractual life of options outstanding as of
December 31, 1999 was approximately 8 years. Options to purchase 720,000 shares
of common stock at a weighted-average exercise price of $0.35 per share were
outstanding and vested at December 31, 1999.
The following table summarizes information concerning options outstanding
and vested as of December 31, 2000 (in thousands, except per share and
remaining contractual life data):
Options Outstanding Options Vested
------------------------------- -------------------
Weighted
Average Weighted- Weighted-
Remaining Average Average
Number of Contractual Exercise Number of Exercise
Exercise Prices Shares Life Price Shares Price
--------------- --------- ----------- --------- --------- ---------
$0.35....................... 1,317 7 $0.35 903 $0.35
$0.70 to $1.50.............. 635 9 0.83 191 0.76
$2.25 to $5.00.............. 245 10 3.35 -- --
----- -----
2,197 8 0.89 1,094 0.42
===== =====
F-16
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The following table summarizes information concerning options outstanding
and vested as of June 30, 2001 (unaudited, in thousands, except per share and
remaining contractual life data):
Options Outstanding Options Vested
------------------------------- -------------------
Weighted
Average Weighted- Weighted-
Remaining Average Average
Number of Contractual Exercise Number of Exercise
Exercise Prices Shares Life Price Shares Price
--------------- --------- ----------- --------- --------- ---------
$0.35....................... 1,071 6 $0.35 755 $0.35
$0.70 to $1.50.............. 582 9 0.84 223 0.74
$2.25 to $3.50.............. 437 9 3.40 1 2.25
$4.25 to $5.00.............. 335 10 4.98 103 4.94
----- -----
2,425 8 1.66 1,082 0.87
===== =====
As of December 31, 2000 and June 30, 2001, approximately 818,000 and
1,455,000 shares of common stock were available for future grant under the
Company's option plans.
Stock Option Compensation
For the year ended December 31, 2000 and for the six months ended June 30,
2001, the Company recorded deferred stock option compensation of $528,000 and
$710,000 in connection with the grant of stock options to employees. Deferred
stock option compensation is the difference between the exercise price of the
options and the fair value of the common stock at the date of grant. Fair value
was determined based on the business factors underlying the value of the
Company's common stock on the date of grant. These amounts were recorded as a
component of stockholders' equity(deficit) and are being amortized as charges
to operations over the vesting period of the options, generally five years
using a graded-vesting method.
The Company has recorded compensation expense for options granted to
consultants in accordance with Emerging Issues Task Force No. 96-18,
"Accounting for Equity Instruments That Are Issued to Other Than Employees for
Acquiring, or in Conjunction with Selling, Goods or Services." The Company
determined the fair value of these options using the Black-Scholes option
pricing model, the estimated fair value of the Company's common stock at the
date of issuance, volatility factor of 0.75, risk-free rate of interest of
5.4%, maximum term of 10 years and no dividend yield.
The Company has recorded stock option compensation expense as follows (in
thousands):
Six Months
Year Ended Ended
December 31, June 30,
-------------- -----------
1998 1999 2000 2000 2001
---- ---- ---- ----- -----
(Unaudited)
Research and development........................... $ 15 $ 12 $199 $ 14 $ 174
Selling, general and administrative................ -- -- 25 -- 127
---- ---- ---- ----- -----
$ 15 $ 12 $224 $ 14 $ 301
==== ==== ==== ===== =====
Amortization of deferred stock option
compensation...................................... $ -- $ -- $ 74 $ -- $ 212
Fair value of options granted to non-employees..... 15 12 150 14 89
---- ---- ---- ----- -----
$ 15 $ 12 $224 $ 14 $ 301
==== ==== ==== ===== =====
In addition, during the year ended December 31, 1999, the Company recognized
interest expense of $8,000 for the fair value of warrants issued in connection
with a credit agreement.
F-17
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Pro Forma Information
Pro forma information regarding net loss applicable to common stockholders
is required by SFAS 123, as if the Company had accounted for its employee stock
options under the fair value method of SFAS 123. Option valuation models
require the input of highly subjective assumptions. Because the Company's
employee stock options have characteristics significantly different from those
of traded options, and because changes in the subjective input assumptions can
materially affect the fair value estimate, in management's opinion, the
existing models do not necessarily provide a reliable measure of the fair value
of its employee stock options.
For purposes of the SFAS 123 pro forma disclosures, the estimated fair value
of the options is amortized to expense over the options' vesting period. The
weighted-average fair value of these options was $0.23 per share, $0.23 per
share and $1.51 per share for the years ended December 31, 1998, 1999 and 2000,
respectively, and $4.59 per share for the six months ended June 30, 2001. The
fair value of these options was estimated at the date of grant using the Black-
Scholes option pricing model and a graded-vesting approach using the following
weighted-average assumptions: volatility factor of 0.75, risk-free interest
rate of 5.4%, weighted-average expected option life of 5 years; and no annual
dividends. The Company's SFAS 123 pro forma net loss applicable to common
stockholders was $4.1 million, $7.0 million, and $10.9 million for the years
ended December 31, 1998, 1999 and 2000, respectively, and $7.0 million for the
six months ended June 30, 2001. The Company's SFAS 123 pro forma net loss per
share applicable to common stockholders was $1.33, $2.23 and $3.16 for the
years ended December 31, 1998, 1999 and 2000, respectively and $1.94 for the
six months ended June 30, 2001. Future pro forma results of operations may be
materially different from amounts reported as future years will include the
effects of additional stock option grants.
9. Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences
between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Significant components
of the Company's deferred tax assets and liabilities are as follows (in
thousands):
Realization of deferred tax assets is dependent upon future earnings, the
timing and amount of which are uncertain. The valuation allowance increased by
$1.6 million and $2.5 million during the years ended December 31, 1998 and
1999, respectively. As of December 31, 2000, the Company had net operating loss
carryforwards of approximately $21.5 million for federal and state income tax
purposes which expire in the years 2010 through 2020 and 2003 through 2010,
respectively. The Company also had approximately $322,000 and $360,000 in
federal and state income tax credits which expire in the years 2010 through
2020.
F-18
AGRAQUEST, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The principal reasons for the difference between the effective income tax
rate and the federal statutory income tax rate of 34% in each year are as
follows:
Year Ended December 31,
-------------------------
1998 1999 2000
------- ------- -------
Federal benefit expected at statutory rate....... $(1,245) $(2,069) $(3,092)
Net operating loss with no current benefit....... 1,245 2,069 3,092
------- ------- -------
Income tax benefit............................... $ -- $ -- $ --
======= ======= =======
Future utilization of the Company's net operating loss and other credit
carryforwards may be subject to substantial annual limitation due to the
ownership change limitations provided by the Internal Revenue Code and similar
state provisions. Such an annual limitation could result in the expiration of
the net operating losses and credits before utilization.
10. 401(k) Plan
Substantially all of the Company's full-time employees are eligible to
participate in a tax deferred investment plan (the "401(k) Plan") established
by the Company. The 401(k) Plan permits each employee to contribute up to 15%
of compensation on a pre-tax basis, to a maximum amount per calendar year. The
Company may provide a discretionary matching contribution to the 401(k) Plan,
which is determined each year by the Company. The Company has provided no
matching contributions to the 401(k) Plan to date.
F-19
Through and including , 2001 (the 25th day after the date of this
prospectus), all dealers effecting transactions in these securities, whether or
not participating in this offering, may be required to deliver a prospectus.
This is in addition to the dealers' obligation to deliver a prospectus when
acting as underwriters and with respect to their unsold allotments or
subscriptions.
Shares
[LOGO OF AGRAQUEST, INC.]
Common Stock
PROSPECTUS
Merrill Lynch & Co.
Stephens Inc.
First Union Securities, Inc.
, 2001
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution.
The expenses to be paid by the Registrant in connection with the
distribution of the securities being registered, other than underwriting
discounts and commissions, are as follows:
Amount*
-------
Securities and Exchange Commission Filing Fee....................... $18,750
NASD Filing Fee..................................................... 8,000
Nasdaq National Market Listing Fee.................................. 5,000
Accounting Fees and Expenses........................................ **
Blue Sky Fees and Expenses.......................................... **
Legal Fees and Expenses.............................................
Transfer Agent and Registrar Fees and Expenses...................... **
Printing Expenses................................................... **
Miscellaneous Expenses.............................................. **
-------
Total............................................................. $
=======
* All amounts are estimates except the SEC filing fee, the NASD filing fee and
the Nasdaq National Market listing fee.
** To be filed by amendment.
Item 14. Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law authorizes a court to
award, or a corporation's board of directors to grant, indemnity to officers,
directors and other corporate agents under certain circumstances and subject to
certain limitations. The Registrant's certificate of incorporation and bylaws
provide that the Registrant shall indemnify its directors, officers, employees
and agents to the full extent permitted by Delaware General Corporation Law,
including in circumstances in which indemnification is otherwise discretionary
under Delaware law. In addition, the Registrant intends to enter into separate
indemnification agreements with its directors, officers and certain employees
which would require the Registrant, among other things, to indemnify them
against certain liabilities which may arise by reason of their status as
directors, officers or certain other employees. The Registrant also intends to
maintain director and officer liability insurance, if available on reasonable
terms.
These indemnification provisions and the indemnification agreement to be
entered into between the Registrant and its officers and directors may be
sufficiently broad to permit indemnification of the Registrant's officers and
directors for liabilities (including reimbursement of expenses incurred)
arising under the Securities Act.
The underwriting agreement, which is Exhibit 1.1 to this registration
statement, provides in Section 6 for indemnification by the underwriters of the
Registrant's officers and directors who sign the Registration Statement for
certain liabilities arising under the Securities Act or otherwise.
Item 15. Recent Sales of Unregistered Securities.
Since January 1, 1998, the Registrant has issued and sold the following
unregistered securities:
1. Between January 1, 1998 and June 30, 2001, the Registrant granted
options to purchase 2,286,072 shares of common stock at prices ranging from
$0.35 to $5.00 to employees, directors and consultants pursuant to its 1995
stock option plan and 2000 stock incentive plan. These issuances were made
in reliance on Rule 701 of the Securities Act.
II-1
2. In March and April 1998, the Registrant issued and sold an aggregate
of 3,523,535 shares of its Series C preferred stock to a total of 17
investors for an aggregate purchase price of $5,991,000. These sales were
made solely to "accredited investors" in reliance on Section 4(2) of the
Securities Act.
3. In December 1998, the Registrant issued a warrant to purchase 31,200
shares of its Series C preferred stock to MMC/GATX Partnership No. 1 and a
warrant to purchase 7,800 shares of its Series C preferred stock to Silicon
Valley Bank. These warrants were issued solely to "accredited investors" in
reliance on Section 4(2) of the Securities Act.
4. From April to September 1999, the Registrant issued and sold an
aggregate of 3,015,306 shares of its Series D preferred stock to a total of
29 investors for an aggregate purchase price of $7,085,000. These sales
were made solely to "accredited investors" in reliance on Section 4(2) of
the Securities Act.
5. In April 2000, the Registrant issued and sold an aggregate of
2,251,919 shares of its Series E preferred stock to a total of 13 investors
for an aggregate purchase price of $7,203,000. These sales were made solely
to "accredited investors" in reliance on Section 4(2) of the Securities
Act.
6. In December 2000, the Registrant issued and sold an aggregate of
2,976,333 shares of its Series F preferred stock to a total of 24 investors
for an aggregate purchase price of $14,965,000. These sales were made
solely to "accredited investors" in reliance on Section 4(2) of the
Securities Act.
The issuances of the securities in the transactions above were deemed to be
exempt from registration under the Securities Act in reliance on Section 4(2)
of the Securities Act promulgated thereunder as transactions by an issuer not
involving a public offering, where the purchasers represented their intention
to acquire the securities for investment only and not with a view to
distribution and received or had access to adequate information about the
Registrant, or Rule 701 promulgated under the Securities Act as transactions
pursuant to a compensatory benefit plan or a written contract relating to
compensation.
Appropriate legends were affixed to the stock certificates issued in the
above transactions. Similar legends were imposed in connection with any
subsequent sales of any such securities. No underwriters were employed in any
of the above transactions.
Item 16. Exhibits and Financial Statement Schedules.
(a) Exhibits
The exhibits are as set forth in the Exhibit Index.
(b) Financial Statement Schedules.
All schedules have been omitted because they are not required or are not
applicable or the required information is shown in the financial statements or
related notes.
Item 17. Undertakings.
The Registrant hereby undertakes to provide to the underwriters at the
closing specified in the Underwriting Agreement certificates in such
denominations and registered in such names as required by the underwriters to
permit prompt delivery to each purchaser.
Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the foregoing provisions, or otherwise, the Registrant
has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense
II-2
of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication
of such issue.
The Registrant hereby undertakes that:
(1) For purposes of determining any liability under the Securities Act,
the information omitted from the form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in a form
of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or
497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective.
(2) For the purpose of determining any liability under the Securities
Act, each post-effective amendment that contains a form of prospectus shall
be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
has duly caused this Amendment No. 1 to the Registration Statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of
Sacramento, State of California on the 3rd day of October 2001.
AgraQuest, Inc.
/s/ Pamela G. Marrone
By: _________________________________
PAMELA G. MARRONE, PH.D.
President and Chief Executive
Officer
Pursuant to the requirements of the Securities Act of 1933, this Amendment
No. 1 to the Registration Statement has been signed by the following persons in
the capacities and on the dates indicated:
Signature Title Date
--------- ----- ----
/s/ Pamela G. Marrone President, Chief Executive October 3, 2001
____________________________________ Officer and Chairman
PAMELA G. MARRONE, PH.D. (Principal Executive
Officer)
** Chief Financial Officer October 3, 2001
____________________________________ (Principal Financial and
DONALD J. GLIDEWELL Accounting Officer)
** Director October 3, 2001
____________________________________
ANN PARTLOW
** Director October 3, 2001
____________________________________
GEORGE E. MYERS
** Director October 3, 2001
____________________________________
FRANK F.C. KUNG, PH.D.
** Director October 3, 2001
____________________________________
JACK HUNT
** Director October 3, 2001
____________________________________
JAMES A. SCHLINDWEIN
** Director October 3, 2001
____________________________________
WALTER LOCHER
II-4
Signature Title Date
--------- ----- ----
** Director October 3, 2001
____________________________________
G. STEVEN BURRILL
** Director October 3, 2001
____________________________________
JOE A. MANCINI
/s/ Pamela G. Marrone
**By: ____________________
PAMELA G. MARRONE, PH.D.
(Attorney-in-fact)
II-5
EXHIBIT INDEX
Exhibit
Number Document
------- --------
1.1* Form of Underwriting Agreement
3.1* Certificate of Incorporation of the Registrant
3.2* Bylaws of the Registrant
4.1 Reference is made to Exhibits 3.1 and 3.2
4.2* Specimen Stock Certificate of the Registrant
4.3** Fourth Amended and Restated Investors' Rights Agreement, dated as of
December 11, 2000, among the Registrant, certain holders of the
Registrant's preferred stock, certain holders of warrants to
purchase the Registrant's capital stock and certain of the
Registrant's founders
5.1* Opinion of Morrison & Foerster LLP
10.1* Form of Indemnification Agreement between the Registrant and each of
its executive officers and directors
10.2** Registrant's 1995 Stock Option Plan, as amended
10.3** 2000 Stock Incentive Plan, as amended
10.4** 2001 Employee Stock Purchase Plan, including forms of agreements
thereunder
10.5** Lease, dated as of July 8, 1998, between the Registrant and Jim
Joseph, as trustee for the Jim Joseph Revocable Trust
10.7*+ Research and Development Agreement, dated as of October 30, 2000,
between the Registrant and Rohm and Haas Company
10.8*+ Strain Access Agreement, dated as of December 21, 2000, between the
Registrant and Maxygen, Inc.
10.9*+ License Agreement dated July 1, 2001 between the Registrant and
Dragoco Gerberding & Co. AG
23.1* Consent of Morrison & Foerster LLP. Reference is made to Exhibit 5.1
23.2 Consent of Ernst & Young LLP, Independent Auditors
24.1 Powers of Attorney. Reference is made to Page II-4
* To be filed by amendment
+ Confidential treatment has been requested with regard to certain portions of
this agreement.
** Previously filed
Exhibit 23.2
Consent of Ernst & Young LLP, Independent Auditors
We consent to the references to our firm under the captions "Selected
Consolidated Financial Data" and "Experts" and to the use of our report dated
January 19, 2001, in Amendment No. 1 to the Registration Statement (Form S-1
No. 333-66732) and related Prospectus of AgraQuest, Inc. for the registration
of its common stock.
/s/ Ernst & Young LLP
Sacramento, California
October 3, 2001